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Angiotensin converting enzyme inhibitors (ACE-Is) and angiotensin receptor blockers (ARBs) 
are the mainstays of therapy for hypertension, heart failure with reduced ejection fraction, and 
coronary artery disease. Additionally, multiple clinical guidelines recommend an ACE-I or ARB 
to be used in chronic kidney disease (CKD) patients with elevated albuminuria. However, how 
albuminuria measures relate to the prescription of ACE-I/ARB is unclear. Despite the benefits of 
ACE-Is and ARBs, they may predispose to hyperkalemia and acute kidney injury, risks that are 
particularly high among patients with low estimated glomerular filtration rate (eGFR). Clinical 
evidence is lacking regarding the risk-benefit balance of discontinuing ACE-I/ARB in patients 
with advanced CKD.  
Using electronic heath records data from the Geisinger Health System, we assessed the 
utilization pattern of ACE-Is and ARBs in real-world clinical practice, and applied causal 
inference tools to investigate the associations of ACE-I/ARB discontinuation with health 
outcomes.  
 In a cohort of individuals without recorded contraindications or allergy to ACE-I/ARB, 
only 43.1% of individuals with albumin-to-creatinine ratio (ACR) > 300 mg/g and 40.9% of 
those with diabetes and ACR >30 mg/g initiated ACE-I/ARB within 6 months of the ACR 
measurement. We also found that individuals with higher levels of albuminuria were more likely 
to initiate ACE-I/ARB, providing evidence that results from albuminuria testing change patient 
care. Among users of ACE-I/ARB, we estimated that the majority had a therapy discontinuation 
by 5 years after therapy initiation. There were strong associations of advanced CKD stages with 
therapy discontinuation, with patients with G4 CKD (eGFR: 15-29 ml/min/1.73 m
2
) more than 
twice as likely to discontinue therapy compared to people with eGFR  90 mL/min/1.73m2. 
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Among users with an eGFR decline to below 30 ml/min/1.73 m
2
, ACE-I/ARB discontinuation 
after the eGFR decline was associated with higher risks of mortality and major adverse 
cardiovascular events, and no significant difference in the risk of end-stage kidney disease.  
In conclusion, continuing ACE-I/ARB in patients with declining renal function may 
provide cardiovascular and survival benefits. However, ACE-I/ARB discontinuation is common 
especially among users with advanced CKD stages. Our findings suggest that adherence to 
albuminuria testing provides an opportunity to enhance utilization of ACE-I/ARB.  
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Chapter 1. Introduction  
Background 
Angiotensin Converting Enzyme Inhibitors (ACE-Is) and Angiotensin Receptor Blockers 
(ARBs) are widely prescribed medications indicated for a number of chronic conditions. 
They are the mainstays of therapy for hypertension, heart failure with reduced ejection 
fraction, and coronary artery disease.
1–6
 Additionally, multiple clinical guidelines 
recommend the use of an ACE-I or ARB in patients with elevated albuminuria,
4,7,8
 as 
these medications provide cardio- and kidney-protective effects, particularly in the 
presence of albuminuria.
1–7,9
 For example, the Kidney Disease Improving Global 
Outcomes (KDIGO) guidelines suggest use of an ACE-I or ARB as an antihypertensive 
agent “in diabetic adults with chronic kidney disease (CKD) and urine albumin excretion 
30–300 mg/24 hours” and “in both diabetic and non-diabetic adults with CKD and urine 
albumin excretion > 300 mg/24 hours”.
7
 In part due to these recommendations, testing for 
albuminuria is suggested for people at higher risk of CKD including those with 
hypertension, diabetes, or 65 years of age or older.
10,11
 However, how the results of 
albuminuria testing relate to the prescription of ACE-I/ARB therapy is uncertain. 
Despite the benefits of ACE-Is and ARBs, they may cause acute reduction in 
glomerular filtration rate (GFR) following their initiation, and also increase the risk of 
hyperkalemia and acute kidney injury.
12–14
 Ultimately, treatment decisions are made 
based on the perceived balance between the benefits and the risks. In the setting of CKD 
progression, the risk-benefit balance may vary as GFR declines. While side effects of 
ACE-I/ARB can affect patients across all CKD stages, some side effects are more 
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concerning in patients with advanced CKD stages. For example, acute reduction in GFR 
can cause more harm for patients with lower GFR. In addition, patients with lower GFR 
are at increased risk of hyperkalemia and acute kidney injury, which can be compounded 
by the use of ACE-Is and ARBs as a result of the potential side-effects. However, the 
renal-protective effect and other benefits may still remain for patients with lower GFR. 
Currently, it is unclear whether risks may start to outweigh benefits as CKD progresses to 
advanced stages, and therefore there remain to be controversies regarding whether ACE-
Is and ARBs should be discontinued in advanced CKD patients.  
Clinical evidence is lacking regarding the efficacy and safety of ACE-I and ARB 
in patients with advanced CKD. This is partly attributable to the fact that patients with 
advanced CKD are generally underrepresented in clinical trials.
15
 Additionally, most 
clinical trial studies are focused on evaluating the efficacy of initiating a therapy; in 
contrast, the impact of treatment discontinuation has been relatively understudied. As a 
result, there is equipoise regarding the risk-benefit balance of discontinuing ACE-I/ARB 
in patients with advanced CKD.
14,16
  
Clinical guidelines reflect this uncertainty and remain vague as to whether ACE-
I/ARB needs to be discontinued in patients with advanced CKD, leaving patients and 
providers to navigate these questions without clear guidance. For example, the Kidney 
Disease Improving Global Outcomes (KDIGO) guideline recommends “temporary 
discontinuation” of ACE-I/ARB “in people with a GFR <60 ml/min/1.73 m
2
 (GFR 
categories G3a-G5) who have serious intercurrent illness that increases the risk of AKI”; 
yet also states “do not routinely discontinue [ACE-I/ARB therapy] in people with GFR 
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 as they remain nephroprotective”.
7
 Currently, discontinuation of 
ACE-I/ARB relies largely on expert opinion in clinical practice. 
Little has been done to assess the pattern of discontinuing ACE-I/ARB across the 
spectrum of kidney function in real-world clinical practice. Existing data on the rates of 
ACE-I/ARB discontinuation largely originated from clinical trials.
17
 A meta-analysis of 
22,542 patients without heart failure across eight randomized controlled trials showed a 
pooled discontinuation rate of 6.5% and 4.9% for ACE-I and ARB users, respectively, 
over an average of 3.4 years of follow-up.
18
 However, drug utilization patterns in clinical 
trials are unlikely to reflect those in real-world practice.  
Objectives 
The overarching goal of this dissertation was to fill the knowledge gap with regards to 
ACE-I/ARB use in the context of CKD. We used electronic health records data from a 
community-based cohort receiving primary care in the Geisinger Health System. 
Specifically, we investigated the following research questions.  
1) We evaluated the association of albuminuria levels with the prescription of ACE-I 
and ARB in real-world clinical practice, given established benefits of ACE-I/ARB in 
patients with elevated albuminuria. We hypothesized that higher levels of ACR would 
be associated with greater utilization of ACE-I/ARB, supporting the notion that 
adherence to albuminuria testing guidelines can change management.  
2) Given the uncertainty regarding whether and when ACE-I/ARB should be 
discontinued in the setting of CKD, we assessed the real-world practice patterns of 
discontinuing ACE-I/ARB across CKD stages and identified factors independently 
associated with ACE-I/ARB discontinuation. We hypothesized that patients with 
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more advanced CKD stage at the time of ACE-I/ARB initiation would be more likely 
to discontinue therapy earlier; hyperkalemia, AKI-related hospitalization, 
hypotension, and low bicarbonate level would be associated with higher risk of ACE-
I/ARB discontinuation; concurrent use of potassium-lowering agents, such as thiazide 
and loop diuretics, would be associated with lower risk of ACE-I/ARB 
discontinuation. 
3) We investigated the association of ACE-I/ARB discontinuation after eGFR declines 
to below 30 ml/min/1.73m
2
 with the risk of mortality, major adverse cardiovascular 
events (MACE), and end-stage kidney disease (ESKD). We hypothesized that ACE-
I/ARB discontinuation would be associated with higher risk of mortality, MACE, and 
ESKD. 
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Chapter 2. Association of Albuminuria Levels with the 
Prescription of Renin-Angiotensin System Blockade 
Abstract 
Multiple clinical guidelines recommend an angiotensin-converting enzyme inhibitor 
(ACE-I) or angiotensin II receptor blocker (ARB) in patients with elevated albuminuria, 
which can be measured through urine albumin-to-creatinine ratio (ACR), protein-to-
creatinine ratio (PCR), or dipstick. However, how albuminuria test results relate to the 
prescription of ACE-I/ARB is uncertain. We identified individuals with an ACR 
measurement between January 1, 2004 and June 30, 2018, and no contraindications or 
allergy to ACE-I/ARB. We performed multivariable logistic regression analyses to 
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evaluate the association between ACR level and prescription of ACE-I/ARB within six 
months after the test. We applied similar methods to investigate the association of PCR 
and dipstick measurement results with the prescription of ACE-I/ARB. Among 67,237 
individuals with an ACR measurement, 47.7% were already taking an ACE-I or ARB at 
the time of first ACR measurement. Among the 35,138 individuals who were not on 
ACE-I/ARB, those with higher ACR levels were more likely to be prescribed ACE-
I/ARB in the following 6 months, with steep increases in prescriptions until ACR 300 
mg/g, after which the association plateaued. The majority (80.9%) of ACE-I/ARB 
prescriptions were made by family medicine and internal medicine. A similar pattern held 
in the cohorts tested by PCR and dipstick measurement. Our study provides evidence that 
albuminuria test results change patient care, suggesting that adherence to albuminuria 
testing is a key step in optimal medical management. 
Key words: albuminuria, urine albumin-to-creatinine ratio, urine protein-to-creatinine 
ratio, antihypertensive, angiotensin converting enzyme inhibitors, angiotensin receptor 
blockers 
Introduction 
Albuminuria, defined as a urine albumin-to-creatinine ratio (ACR) ≥ 30 mg/g, is a 
pathologic condition which reflects kidney damage.
1–3
 Higher levels of albuminuria are 
associated with increased risks of adverse kidney events such as end-stage kidney disease, 
decline in eGFR, and acute kidney injury.
4–6
 Additionally, higher levels of albuminuria 
are associated with greater risks of hypertension, cardiovascular events, and all-cause 
mortality.
4,5,7–11
 Multiple clinical guidelines recommend the use of an angiotensin-
converting enzyme inhibitor (ACE-I) or angiotensin II receptor blocker (ARB) in patients 
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 as these medications provide cardio- and kidney-
protective effects, particularly in the presence of albuminuria.
1,12,14–19
 For example, the 
Kidney Disease Improving Global Outcomes (KDIGO) guidelines suggest use of an 
ACE-I or ARB as an antihypertensive agent “in diabetic adults with chronic kidney 
disease (CKD) and urine albumin excretion 30–300 mg/24 hours” and “in both diabetic 
and non-diabetic adults with CKD and urine albumin excretion > 300 mg/24 hours”.
1
 
Similarly, the American Diabetes Association suggests that “in nonpregnant patients with 
diabetes and hypertension, either an ACE inhibitor or an angiotensin receptor blocker is 
recommended for those with modestly elevated urinary albumin-to-creatinine ratio (30–
299 mg/g creatinine) and is strongly recommended for those with urinary albumin-to-
creatinine ratio ≥ 300 mg/g creatinine”.
20
  
In part due to these recommendations, testing for albuminuria is suggested for 
people at higher risk of CKD including those with hypertension, diabetes, or 65 years of 
age or older.
21,22
 Urine ACR is considered the preferred method of measuring 
albuminuria, followed by urine protein-to-creatinine ratio (PCR), and urine protein 
dipstick measurement.
1
 Urine ACR between 30 and 300 mg/g and PCR between 150 and 
500 mg/g are considered “moderately increased” albuminuria; ACR above 300 mg/g and 
PCR above 500 mg/g are considered “severely increased” albuminuria.
1
 We previously 
reported that patients who received testing for albuminuria had a lower risk of ACE-
I/ARB discontinuation.
23
 However, how the results of albuminuria testing relate to the 
prescription of ACE-I/ARB therapy is uncertain.  
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Using data from a large, integrated health care system, we identified individuals 
who received an ACR measurement and studied the association of ACR level with the 
utilization of ACE-I/ARB. We hypothesized that higher levels of ACR would be 
associated with higher odds of ACE-I/ARB initiation, supporting the notion that 
adherence to albuminuria testing guidelines can change management. To discern specific 
patterns for different albuminuria measurement methods, we also assessed the 
associations of PCR and dipstick measurement results with the prescription of ACE-
I/ARB.  
Methods 
Study setting and study population 
We identified a real-world cohort of individuals who received testing for albuminuria 
using data from Geisinger, an integrated health system serving 45 counties across central 
and northeastern Pennsylvania. The electronic health records of the system provide data 
on patient demographic characteristics, inpatient and outpatient encounters, problem lists, 
outpatient prescriptions, and laboratory test results.  
We identified 83,807 individuals who received an ACR measurement between 
January 1, 2004 and June 30, 2018. Time of the first ACR measurement was considered 
the baseline date for each individual. We excluded individuals with any record of allergy 
to ACE-I/ARB at the time of the ACR measurement (n=3,285). Next, we excluded 
individuals whose systolic blood pressure was missing or below 100 mmHg based on the 
latest outpatient measure prior to the time of the ACR measurement (n=4,309), and those 
with the latest outpatient serum potassium above 5 mEq/L or no serum potassium 
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measured at or before the time of the ACR measurement (n=6,893). Further exclusion 
criteria included end-stage kidney disease (n=318), pregnancy within the preceding year 
(n=1,294), age < 18 years (n=435), and no serum creatinine measurement by the time of 
the ACR measurement (n=36; Figure S1).  
Exposure 
The primary exposure of interest was ACR, which we log-transformed with a base of 2. 
To allow for a potentially non-linear relationship, we used linear spline forms of log-
transformed ACR with knots corresponding to ACR values at 30 and 300 mg/g. 
Outcomes 
Prevalent use of ACE-I/ARB was defined as any record of ACE-I/ARB use during the 
three-month period prior to the ACR measurement. Among individuals who were not 
prevalent users of ACE-I/ARB, we investigated new prescription of ACE-I/ARB 
initiation within six months after the ACR measurement. 
Baseline covariates 
Systolic blood pressure, serum potassium, and serum creatinine at the time of the ACR 
testing were defined as the most recent antecedent outpatient measure. Glomerular 
filtration rate (GFR) was estimated using serum creatinine accounting for age, sex, and 
race based on the CKD Epidemiology Collaboration equation.
24
 We used linear spline 
forms of eGFR with knots at 30 and 60 mL/min/1.73 m
2
. We ascertained baseline 
comorbidities such as diabetes, congestive heart failure, myocardial infarction, and 
hypertension through the International Classification of Diseases, Ninth Revision, 
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Clinical Modification (ICD-9-CM) and the International Classification of Diseases, Tenth 
Revision, Clinical Modification (ICD-10-CM) codes (Table S1). Data regarding statin, 
thiazide, calcium channel blocker, and beta blocker use at the time of the ACR testing 
were obtained from medication records. We also obtained demographic characteristics 
such as age, sex, and race/ethnicity. Calendar year at the time of the ACR testing was 
categorized into 2004-2008, 2009-2013, and 2014-2018.  
Statistical analyses 
Baseline characteristics of the study population were described using median 
(interquartile range) for ACR, mean (standard deviation [SD]) for other continuous 
variables, and count (percentage) for categorical variables. We performed multivariable 
logistic regression to assess the association of ACR level and other covariates with the 
prevalent use of ACE-I/ARB at the time of the ACR measurement.  
Among individuals not on ACE-I/ARB at the time of the ACR test, we used 
kernel density curves to depict the distribution of log-transformed ACR levels stratified 
by ACE-I/ARB initiation status. We then performed multivariable logistic regression 
analyses to evaluate the association between ACR level and ACE-I/ARB initiation within 
six months of the ACR test, adjusting for baseline age, sex, race/ethnicity, calendar year 
of the ACR test, systolic blood pressure, serum potassium, eGFR, diabetes, congestive 
heart failure, myocardial infarction, hypertension, use of statin, thiazide, calcium channel 
blocker, and beta blocker.  
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Finally, among individuals who initiated ACE-I/ARB within 6 months of the 
ACR measurement, we assessed the proportion prescribed by providers of different 
specialties. 
Additional analyses 
We investigated associations of PCR and dipstick test result with ACE-I/ARB 
prescription. We applied similar inclusion criteria as described above and identified a 
cohort of 20,104 adults who received their first PCR measurement between January 1, 
2004 and June 30, 2018, and 141,914 adults who received their first dipstick 
measurement during the same period. PCR was also log-transformed with a base of 2 and 
it was modeled using spline terms with a knot corresponding to PCR at 500 mg/g given 
the shape of the association as well as the clinical use of this threshold. Dipstick 
measurement result was treated as a categorical variable with “++ or above”, “+”, and 
“trace or negative” as the reference category. A similar analytic procedure was performed 
for each of these cohorts. 
For all analyses, statistical significance was evaluated at a significance level of 0.05 
based on two-sided testing. SAS software, version 9.4 (SAS Institute Inc), Stata, version 
15.1 (StataCorp LLC), and R, version 3.6.0 (R Foundation for Statistical Computing) 
were used for statistical analyses.  
This study was approved by institutional review boards at the Johns Hopkins Bloomberg 
School of Public Health and Geisinger Medical Center. All data were deidentified, and 
consent was waived. 
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There were a total of 67,237 individuals who had an ACR measurement and met the 
inclusion criteria (Table 2-1). Mean (SD) age of the cohort was 60.5 (14.9) years and 
33,696 (50.1%) were female. The majority of the cohort had a clinical diagnosis of 
diabetes (n=36,722, 54.6%) or hypertension (n=49,530, 73.7%). Mean (SD) eGFR was 
81 (24.1) mL/min/1.73 m
2
, and 14,189 (21.1%) individuals had an eGFR below 60 
mL/min/1.73 m
2
 at the time of the ACR test. Median (interquartile range) ACR was 9 (4-
26) mg/g. ACR ranged between 30 and 300 mg/g for 12,522 (18.6%) individuals and was 
above 300 mg/g for 2,927 (4.4%) individuals.  
Association between ACR level and prevalent use of ACE-I/ARB 
A total of 32,099 (47.7%) individuals were on ACE-I/ARB therapy at the time of the 
initial ACR test. Individuals who were taking ACE-I/ARB therapy were more likely to 
have higher ACR (odds ratio (OR) per two-fold higher level: 1.11 [95% confidence 
interval (CI): 1.10-1.12]), serum potassium (OR per mEq/L higher level: 1.45 [95% CI: 
1.38-1.52]), systolic blood pressure (OR per 10-mmHg higher level: 1.13 [95% CI: 1.12-
1.14]), and eGFR (OR per 5 mL/min/1.73 m
2
 higher level: 1.90 [95% CI: 1.70-2.12] for 
eGFR below 30 mL/min/1.73 m
2
; 1.02 [95% CI: 1.01-1.04] for eGFR between 30 and 60 
mL/min/1.73 m
2
; and 1.01 [95% CI: 1.00-1.02] for eGFR above 60 mL/min/1.73 m
2
). 
Additionally, ACE-I/ARB use at the time of the test was positively associated with the 
presence of diabetes (OR: 1.17 [95% CI: 1.13-1.21]), congestive heart failure (OR: 1.11 
[95% CI: 1.04-1.19]), hypertension (OR: 3.77 [95% CI: 3.59-3.95]), statin use (OR: 1.46 
ACE Inhibitors and ARBs in the Setting of Chronic Kidney Disease  
Thesis Dissertation | Yao Qiao 
 
 15 
[95% CI: 1.41-1.51]), thiazide use (OR: 1.61 [95% CI: 1.55-1.67]), and black race (OR: 
1.23 [95% CI: 1.12-1.34]), and negatively associated with beta blocker use (OR: 0.83 [95% 
CI: 0.80-0.86]), older age (OR per 10-year higher age: 0.94 [95% CI: 0.92-0.95]), female 
sex (OR: 0.94 [95% CI: 0.91-0.98]), and more recent years (OR: 0.88 [95% CI: 0.84-0.92] 
and 0.86 [95% CI: 0.82-0.89] for year 2009-2013 and 2014-2018, respectively, compared 
with year 2004-2008).  
Association between ACR level and initiation of ACE-I/ARB  
Among the 35,138 individuals who were not on ACE-I/ARB at the time of the test, 6,514 
(18.5%) initiated ACE-I/ARB within 6 months. The proportion who initiated an ACE-
I/ARB was 13.6%, 35.6%, and 43.1% among individuals with ACR <30, 30-300, and 
>300 mg/g, respectively. Among the 4,621 individuals with diabetes and ACR above 30 
mg/g, 1,889 (40.9%) initiated ACE-I/ARB. Among the 426 individuals with ACR above 
300 mg/g and no diabetes, 162 (38.0%) initiated ACE-I/ARB. Those who initiated ACE-
I/ARB had a distribution of ACR more skewed toward higher levels than those who did 
not (Figure 2-1). Multivariable logistic regression showed significantly higher odds of 
initiating ACE-I/ARB with higher levels of ACR for ACR below 30 mg/g (OR per two-
fold higher ACR: 1.33 [95% CI: 1.30-1.37]) and between 30 and 300 mg/g (OR: 1.34 [95% 
CI: 1.29-1.40]), but no significant difference associated with further increase in ACR 
above 300 mg/g (OR: 1.01 [95% CI: 0.93-1.10]; Figure 2-2). Additionally, ACE-I/ARB 
initiation within six months of the ACR measurement was positively associated with 
higher serum potassium, systolic blood pressure, eGFR, statin use, thiazide use, black 
race, the presence of diabetes, and hypertension, and was negatively associated with beta 
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blocker use, calcium channel blocker use, previous diagnosis of congestive heart failure, 
older age, female sex, and more recent years (Table 2-2). Among those who initiated 
ACE-I/ARB, 80.9% were prescribed by family medicine and internal medicine, 1.8% by 
endocrinologists, 1.5% by cardiologists, 1.4% by nephrologists, 1.0% by emergency 
medicine, and the remaining 13.4% by providers of other specialties.   
Results in cohorts with PCR and dipstick measurement 
A total of 20,104 individuals with a PCR measurement and 141,914 individuals with a 
dipstick measurement met the inclusion criteria (Table 2-S 2, 2-S 3). Compared with the 
cohort tested with ACR, prevalence of diabetes was lower in the PCR and dipstick 
cohorts (33.4% and 15.3% vs. 54.6%). In contrast, the proportion with eGFR below 60 
mL/min/1.73 m
2 
was the highest among those tested by PCR (57.2%), followed by ACR 
(21.1%), and dipstick (12.6%). The majority had hypertension among those tested by 
PCR (79.3%) and ACR (73.7%), but less than half had hypertension by the time of the 
initial dipstick measurement (46.9%). 
 Among the 20,104 individuals who had a PCR measurement, median 
(interquartile range) PCR was 110 (68-260) mg/g, and 10437 (51.9%) individuals were 
on ACE-I/ARB therapy at the time of the initial PCR test. Individuals who were taking 
ACE-I/ARB therapy were more likely to have higher PCR only for those with PCR above 
500 mg/g (OR per two-fold higher PCR: 1.07 [95% CI: 1.02-1.12]), adjusting for 
baseline covariates. Interestingly, there was an inverse association between higher levels 
of PCR and prevalent use of ACE-I/ARB for PCR below 500 mg/g (OR per two-fold 
higher PCR: 0.94 [95% CI: 0.91-0.97]).   
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Of the 9,667 individuals who were not on ACE-I/ARB at the time of the PCR test, 
912 (9.4%) initiated ACE-I/ARB within 6 months. Individuals who initiated ACE-I/ARB 
within 6 months of the PCR test had a distribution of PCR levels that was more skewed 
toward the higher range, compared with those did not initiate ACE-I/ARB (Figure 2-S 2). 
Higher PCR was independently associated with a significantly higher odds of ACE-
I/ARB initiation (OR per two-fold increase in PCR: 1.47 [95% CI: 1.36-1.58] for PCR 
below 500 mg/g and 1.35 [95% CI: 1.23-1.48] for PCR above 500 mg/g; Figure 2-S 3). 
Among those who initiated ACE-I/ARB, 45.8% were prescribed by family medicine and 
internal medicine, 29.6% by nephrologists, 2.4% by cardiologists, 1.9% by emergency 
medicine, 0.9% by endocrinologists, and the remaining 19.4% by providers of other 
specialties. 
Among the 141,914 patients who received a dipstick measurement, 39,664 
(27.9%) individuals were on ACE-I/ARB therapy at the time of the initial dipstick 
measurement. Compared with a negative dipstick test result, having a result of “+”was 
negatively associated with prevalent ACE-I/ARB use (OR: 0.95 [95% CI: 0.91-0.99]); 
whereas a result of “++ or above” was not associated with a significant difference in 
prevalent ACE-I/ARB use (OR: 1.09 [95% CI: 0.99-1.21]). 
Among the 102,250 individuals who were not on ACE-I/ARB at the time of the 
dipstick measurement, 5,234 (5.1%) initiated ACE-I/ARB within 6 months. Compared 
with a negative test result, both results of “+” (OR: 1.25 [95% CI: 1.16-1.36]) and “++ or 
above” (OR: 1.54 [95% CI: 1.29-1.84]) were independently associated with a higher odds 
of ACE-I/ARB initiation within 6 months of the test. Among those who initiated ACE-
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I/ARB, 78.5% were prescribed by family medicine and internal medicine, 3.4% by 
cardiologists, 2.9% by nephrologists, 1.0% by emergency medicine, 0.6% by 
endocrinologists, and the remaining 13.6% by providers of other specialties.   
Discussion 
Our study investigated the utilization of ACE-I/ARB in a large, real-world patient cohort 
who were tested for albuminuria. Almost half were already on ACE-I/ARB at the time of 
the initial ACR test. Those on ACE-I/ARB at the time of the test were more likely to 
have hypertension, diabetes, and congestive heart failure, which is not surprising given 
established benefits of ACE-I/ARB for these conditions.
1,12,14,15,17
 Interestingly, older 
individuals were less likely to be on ACE-I/ARB at the time of the test. This finding was 
consistent with previous studies that observed underutilization of ACE-I/ARB among 
older adults.
25,26
 Among individuals not already taking ACE-I/ARB at the time of the 
albuminuria test, higher ACR was positively associated with initiating ACE-I/ARB in the 
subsequent six months. Interestingly, the association plateaued for ACR levels above 300 
mg/g; in other words, although an individual with ACR 1000 mg/g was much more likely 
to be prescribed an ACE-I/ARB than someone whose test showed ACR 29 mg/g, the 
individual was not more likely to be prescribed an ACE-I/ARB than someone with ACR 
300 mg/g. In comparison, higher PCR was positively associated with ACE-I/ARB 
initiation for PCR levels both above and below 500 mg/g. This observation may reflect 
the fact that ACR above 300 mg/g is an unambiguous indication for prescribing ACE-
I/ARB, with no difference in guidance with respect to ACE-I/ARB prescription once 
ACR passes the threshold of 300 mg/g. In comparison, the conversion of PCR to ACR is 
approximate, with less clear guidance on when to initiate an ACE-I/ARB, which may 
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explain a positive association between PCR levels and ACE-I/ARB initiation across the 
whole range of PCR. Alternatively, it may reflect the specialty of the provider who 
managed the patients. Nephrologists may be more likely to both order PCR measurement 
to test for albuminuria and to prescribe ACE-I/ARB therapy. For example, among 
individuals who were prescribed ACE-I/ARB following a PCR measurement, 29.6% 
received prescriptions from nephrologists, compared with 1.4% among those who 
initiated ACE-I/ARB following an ACR measurement. Similarly, cardiologists’ 
prescription of ACE-I/ARB therapy was higher in patients with PCR measured compared 
to ACR.  
This study suggests that some providers follow clinical guidelines recommending 
ACE-I/ARB use in individuals with elevated albuminuria, however, many others do not. 
For example, in this cohort of individuals without recorded contraindications to ACE-
I/ARB such as hyperkalemia, hypotension, or allergy to ACE-I/ARB, only 43.1% of 
those with ACR > 300 mg/g and only 40.9% of individuals with diabetes and ACR >30 
mg/g initiated ACE-I/ARB within 6 months of the test. Underutilization of ACE-I/ARB 
was also observed in a previous study reporting that 54% of the diabetic patients with 
albuminuria received ACE-I/ARB.
27
 Of note, these utilization rates were obtained among 
individuals who were tested for albuminuria. Underutilization would likely be higher 
among individuals who do not undergo albuminuria testing.  
While individuals with previous diagnosis of congestive heart failure were more 
likely to be on ACE-I/ARB at the time of the ACR measurement, those who were not on 
ACE-I/ARB at the time of the ACR measurement were less likely to initiate ACE-I/ARB 
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after the ACR measurement. This may reflect selection bias: those who were not on 
ACE-I/ARB already may have intolerance or a contraindication to therapy. However, 
previous studies suggest underutilization of ACE-I/ARB among individuals with 
congestive heart failure may be due to fear of adverse events such as kidney function 
deterioration and hypotension, and insufficient appreciation of the benefits of these 
medications or the prognostic implications of heart failure.
28–30
 Our findings similarly 
highlight underutilization of ACE-I/ARB among individuals with elevated albuminuria. 
Given that the majority of the population received prescriptions from family medicine 
and internal medicine providers, educational efforts focused on these providers may help 
overcome barriers of ACE-I/ARB utilization among individuals with elevated 
albuminuria.  
There are several limitations of this study. First, we used medication prescription 
records to ascertain ACE-I/ARB use. Therefore, our study results reflect the pattern in 
ACE-I/ARB prescription rather than the actual dispensing or use of these medications. 
Second, data were not captured for drug classes such as sodium-glucose cotransporter 2 
inhibitors or glucagon-like peptide 1 receptor agonists, since randomized controlled trials 
supporting their indications in individuals with albuminuria were first published near the 
end of the study period. Third, the study cohort was mainly white and our findings may 
thus have limited generalizability to other racial and ethnicity groups. Fourth, 
albuminuria level was based on only one measurement. Fifth, we did not take dosage into 
consideration. Future studies are needed to evaluate dosage of ACE-I/ARB in real-world 
clinical practice to examine potential opportunities to maximize therapeutic potential. 
Sixth, our study was from a primarily rural setting, which may have limited access to 
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specialty care. Therefore, the observed ACE-I/ARB utilization patterns may not 
generalize to urban settings. Finally, we were unable to account for socioeconomic status.  
Our study assessed the association between albuminuria test results and the 
prescription of ACE-I/ARB in a large, integrated health system. We examined the pattern 
for patients with ACR, PCR, and dipstick measurement individually. Instead of 
categorizing ACR and PCR values into “normal to mildly increased”, “moderately 
increased” and “severely increased” albuminuria, we evaluated a continuous form of 
these variables with splines in the model to provide insights on the effect of increase in 
the measurement within each category while comprehensively addressing indications and 
contraindications for the initiation of ACE-I/ARB. Finally, we excluded people with 
recorded allergies to ACE-I/ARB.  
Conclusion 
Using data from a large, integrated health system, we found that higher levels of ACR 
were associated with a higher likelihood of initiating ACE-I/ARB, thus albumuria testing 
may be helpful in prompting the initiation of ACE-I/ARBs among some individuals. 
However, even among those with the highest levels of ACR, many individuals who may 
have been eligible for treatment with ACE-I/ARB were not initiated on them. A similar 
trend was found for other methods of albuminuria testing including PCR and dipstick 
measurement. These results provide evidence that results from albuminuria testing 
change patient care, suggesting that adherence to albuminuria testing is a key step in 
optimal medical management.  
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Figure 2- 1. Distribution of ACR stratified by ACE-I/ARB initiation within six months 
of the ACR test among individuals not on ACE-I/ARB at the time of the test (N=35,138), 
displayed on a log scale 
 
Abbreviations: ACR, albumin-to-creatinine ratio; ACE-I/ARB: angiotensin-converting 
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Figure 2- 2. Association* between ACR and initiation of ACE-I/ARB among individuals 
not on ACE-I/ARB at the time of the ACR test (N=35,138) 
 
 
*Reference point at ACR 10 mg/g; adjusted for baseline age, sex, race/ethnicity, calendar 
year, systolic blood pressure, serum potassium, estimated glomerular filtration rate, 
diabetes, congestive heart failure, myocardial infarction, hypertension, use of statin, 
thiazide, calcium channel blocker, and beta blocker 
Abbreviations: ACR, albumin-to-creatinine ratio; ACE-I/ARB: angiotensin-converting 
enzyme inhibitor or angiotensin II receptor blocker 
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Table 2- 1. Characteristics of the patient cohort who received urine ACR measurement 
Patient characteristics Overall Baseline use of ACE-I/ARB 
Yes No 
Total number, N 67237 32099 35138 
Urine ACR, median (IQR), mg/g 9 (4-26) 10 (4-29) 8 (4-23) 
Age, mean (SD), years 60.5 (14.9) 62.7 (13.6) 58.4 (15.7) 
Systolic blood pressure, mean (SD), mmHg 130 (16.4) 131 (16.8) 129 (15.9) 
Potassium, mean (SD), mEq/L 4.3 (0.4) 4.3 (0.4) 4.3 (0.4) 
eGFR, mean (SD), mL/min/1.73m
2
 81 (24.1) 78 (23.2) 84 (24.4) 
Female sex, N (%) 33696 (50.1) 15171 (47.3) 18525 (52.7) 
Black race, N (%) 2526 (3.8) 1190 (3.7) 1336 (3.8) 
Diabetes, N (%) 36722 (54.6) 17853 (55.6) 18869 (53.7) 
Congestive heart failure, N (%) 4769 (7.1) 2969 (9.3) 1800 (5.1) 
Hypertension, N (%) 49530 (73.7) 29979 (93.4) 19551 (55.6) 
Myocardial infarction, N (%) 4073 (6.1) 2604 (8.1) 1469 (4.2) 
Thiazide diuretics, N (%) 17623 (26.2) 11646 (36.3) 5977 (17.0) 
Calcium channel blockers, N (%) 11504 (17.1) 7152 (22.3) 4352 (12.4) 
Beta blockers, N (%) 23270 (34.6) 12990 (40.5) 10280 (29.3) 
Statin, N (%) 31235 (46.5) 18173 (56.6) 13062 (37.2) 
Calendar year, N (%)    
2004-2008 16719 (24.9) 6785 (21.1) 9934 (28.3) 
2009-2013 20898 (31.1) 10192 (31.8) 10706 (30.5) 
2014-2018 29620 (44.1) 15122 (47.1) 14498 (41.3) 
 
Abbreviations: ACR, albumin-to-creatinine ratio; IQR: interquartile range; SD, standard 
deviation; ACE-I/ARB: angiotensin-converting enzyme inhibitor or angiotensin II 
receptor blocker; eGFR: estimated glomerular filtration rate 
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Table 2- 2. Associations of patient characteristics with the initiation of ACE-I/ARB among 
individuals not on ACE-I/ARB at the time of the ACR test (N=35,138) 
Patient characteristics Odds ratio (95% CI) 
Urine ACR, per two-fold higher 
 ACR below 30 mg/g 1.33 (1.30-1.37) 
ACR between 30 and 300 mg/g 1.34 (1.29-1.40) 
ACR above 300 mg/g 1.01 (0.93-1.10) 
Age, per 10-year higher 0.86 (0.84-0.88) 
Female sex 0.89 (0.83-0.94) 
Black race 1.48 (1.29-1.70) 
Systolic blood pressure, per 10-mmHg higher 1.32 (1.30-1.35) 
Potassium, per mEq/L higher 1.24 (1.15-1.35) 
eGFR, per 5-mL/min/1.73 m
2
 higher 
 eGFR below 30 mL/min/1.73 m
2
 2.06 (1.63-2.60) 
eGFR between 30 and 60 mL/min/1.73 m
2
 1.09 (1.05-1.12) 
eGFR above 60 mL/min/1.73 m
2
 1.02 (1.01-1.03) 
Diabetes 1.46 (1.38-1.56) 
Congestive heart failure 0.80 (0.69-0.93) 
Hypertension 1.95 (1.82-2.10) 
Myocardial infarction 0.92 (0.79-1.08) 
Thiazide diuretics 1.40 (1.30-1.52) 
Calcium channel blockers 0.89 (0.81-0.97) 
Beta blockers 0.82 (0.77-0.89) 
Statin 1.33 (1.25-1.42) 
Calendar year, 2004-2008 as reference 
 2009-2013 0.78 (0.73-0.84) 
2014-2018 0.60 (0.56-0.64) 
 
Abbreviations: ACE-I/ARB: angiotensin-converting enzyme inhibitor or angiotensin II receptor 
blocker; ACR, albumin-to-creatinine ratio; eGFR: estimated glomerular filtration rate; CI, 
confidence interval 
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Supplement 
Table 2-S 1. International Classification of Disease, 9th and 10th Editions, Clinical Modification 
(ICD-9-CM, ICD-10-CM) Used to Define Disease Conditions 
Disease condition ICD-9-CM codes ICD-10-CM codes 
Diabetes 250.x  E10.x, E11.x, E13.x  
Congestive heart failure 428.x I50.x 
Myocardial infarction 
410.00, 410.0, 410.01, 410.02, 
410.1, 410.10, 410.11, 410.12, 
410.20, 410.2, 410.21,  
410.22, 410.30, 410.31, 410.32, 
410.40, 410.4, 410.41, 410.42, 
410.50, 410.51, 410.52,  
410.60, 410.61, 410.62, 410.7, 
410.70, 410.71, 410.72, 410.8, 
410.80, 410.81, 410.82,  
410.9, 410.90, 410.91, 410.92, 
411.0, 412, 429.7, 429.71, 
429.79 
I24.1, I25.2, I51.0, I21.x-
I23.x 
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Table 2-S 2. Characteristics of the patient cohort who received urine PCR measurement 
Patient characteristics Overall Baseline use of ACE-I/ARB 
Yes No 
Total number, N 20104 10437 9667 
Urine PCR, median (IQR), mg/g 110 (68-260) 116 (70-290) 100 (60-220) 
Age, mean (SD), years 64.2 (16.5) 67.4 (13.9) 60.8 (18.3) 
Systolic blood pressure, mean (SD), mmHg 130.8 (17.9) 132.9 (18.3) 128.4 (17.2) 
Potassium, mean (SD), mEq/L 4.3 (0.4) 4.3 (0.4) 4.2 (0.4) 
eGFR, mean (SD), mL/min/1.73m
2
 61.1 (28.0) 57.2 (24.9) 65.2 (30.5) 
Female sex, N (%) 11305 (56.2) 5473 (52.4) 5832 (60.3) 
Black race, N (%) 475 (2.4) 237 (2.3) 238 (2.5) 
Diabetes, N (%) 6710 (33.4) 4740 (45.4) 1970 (20.4) 
Congestive heart failure, N (%) 2986 (14.9) 1860 (17.8) 1126 (11.7) 
Hypertension, N (%) 15940 (79.3) 10008 (95.9) 5932 (61.4) 
Myocardial infarction, N (%) 1874 (9.3) 1247 (12.0) 627 (6.5) 
Thiazide diuretics, N (%) 4966 (24.7) 3441 (33.0) 1525 (15.8) 
Calcium channel blockers, N (%) 5254 (26.1) 3340 (32.0) 1914 (19.8) 
Beta blockers, N (%) 9246 (46.0) 5645 (54.1) 3601 (37.3) 
Statin, N (%) 10128 (50.4) 6603 (63.3) 3525 (36.5) 
Calendar year, N (%)    
2004-2008 2583 (12.9) 1232 (11.8) 1351 (14.0) 
2009-2013 7493 (37.3) 3798 (36.4) 3695 (38.2) 
2014-2018 10028 (49.9) 5407 (51.8) 4621 (47.8) 
 
Abbreviations: PCR, protein-to-creatinine ratio; IQR: interquartile range; SD, standard deviation; 
ACE-I/ARB: angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker; eGFR: 
estimated glomerular filtration rate   
 
 
 ACE Inhibitors and ARBs in the Setting of Chronic Kidney Disease  
Thesis Dissertation | Yao Qiao 
 33 
Table 2-S 3. Characteristics of the patient cohort who received urine dipstick measurement 
Patient characteristics Overall Baseline use of ACE-I/ARB 
Yes No 
Total number, N 141914 39664 102250 
Urine dipstick measure, N (%)    
"Negative"  118951 (83.8) 31960 (80.6) 86991 (85.1) 
"+" 19854 (14.0) 6489 (16.4) 13365 (13.1) 
"++ or above" 3109 (2.2) 1215 (3.1) 1894 (1.9) 
Age, mean (SD), years 54.2 (17.7) 63.1 (13.9) 50.8 (17.8) 
Systolic blood pressure, mean (SD), mmHg 128 (17.1) 133 (17.8) 126 (16.4) 
Potassium, mean (SD), mEq/L 4.2 (0.4) 4.3 (0.4) 4.2 (0.4) 
eGFR, mean (SD), mL/min/1.73m
2
 88 (23.9) 77 (22.9) 92 (23.1) 
Female sex, N (%) 78052 (55.0) 19322 (48.7) 58730 (57.4) 
Black race, N (%) 4850 (3.4) 1319 (3.3) 3531 (3.5) 
Diabetes, N (%) 21701 (15.3) 13161 (33.2) 8540 (8.4) 
Congestive heart failure, N (%) 6059 (4.3) 3493 (8.8) 2566 (2.5) 
Hypertension, N (%) 66597 (46.9) 36758 (92.7) 29839 (29.2) 
Myocardial infarction, N (%) 4951 (3.5) 2876 (7.3) 2075 (2.0) 
Thiazide diuretics, N (%) 21544 (15.2) 13582 (34.2) 7962 (7.8) 
Calcium channel blockers, N (%) 15446 (10.9) 8900 (22.4) 6546 (6.4) 
Beta blockers, N (%) 30294 (21.4) 14998 (37.8) 15296 (15.0) 
Statin, N (%) 38297 (27.0) 20143 (50.8) 18154 (17.8) 
Calendar year, N (%)    
2004-2008 35432 (25.0) 7437 (18.8) 27995 (27.4) 
2009-2013 42547 (30.0) 12094 (30.5) 30453 (29.8) 
2014-2018 63935 (45.1) 20133 (50.8) 43802 (42.8) 
 
Abbreviations: IQR: interquartile range; SD, standard deviation; ACE-I/ARB: angiotensin-
converting enzyme inhibitor or angiotensin II receptor blocker; eGFR: estimated glomerular 
filtration rate   
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Figure 2-S 1. Derivation of study cohort 
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Figure 2-S 2. Distribution of PCR stratified by ACE-I/ARB initiation within six months of the 




Abbreviations: PCR, protein-to-creatinine ratio; ACE-I/ARB: angiotensin-converting enzyme 
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Figure 2-S 3. Association between PCR and initiation of ACE-I/ARB among individuals not on 
ACE-I/ARB at the time of the PCR test (N=9,667) 
 
 
*Reference point at PCR 150 mg/g; adjusted for baseline age, sex, race/ethnicity, calendar year, 
systolic blood pressure, serum potassium, estimated glomerular filtration rate, diabetes, 
congestive heart failure, myocardial infarction, hypertension, use of statin, thiazide, calcium 
channel blocker, and beta blocker. 
Abbreviations: PCR, protein-to-creatinine ratio; ACE-I/ARB: angiotensin-converting enzyme 
inhibitor or angiotensin II receptor blocker 
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Chapter 3. Discontinuation of Angiotensin Converting Enzyme 
Inhibitors and Angiotensin Receptor Blockers in Chronic Kidney 
Disease 
Abstract 
Objective: To assess the patterns of angiotensin converting enzyme inhibitors and angiotensin 
receptor blockers (ACE-I/ARB) discontinuation in the setting of chronic kidney disease (CKD) 
progression in real-world clinical practice.  
Patients and Methods: We identified incident ACE-I/ARB users with a baseline estimated 
glomerular filtration rate (eGFR) ≥15mL/min/1.73m
2
 and without end-stage renal disease in the 
Geisinger Health System between January 1, 2004 and December 31, 2015. We investigated the 
associations of CKD stage, hospitalizations with and without acute kidney injury (AKI), serum 
potassium, bicarbonate level, thiazide, and loop diuretic use with ACE-I/ARB discontinuation. 
Results: Among the 53,912 ACE-I/ARB users, the mean age was 59.9 years and 50.6% were 
female. Over half discontinued ACE-I/ARB within 5 years of therapy initiation. The risk of 
ACE-I/ARB discontinuation increased with more advanced CKD stage. For example, patients 
who initiated ACE-I/ARB with CKD stage G4 (eGFR: 15-29ml/min/1.73m
2
) were 2.09-times 
[95% CI: 1.87-2.34] more likely to discontinue therapy than those with eGFR≥90ml/min/1.73m
2
. 
Potassium level>5.3mEq/L, systolic blood pressure 90mmHg, bicarbonate level<22mmol/L, 
and intervening hospitalization – particularly AKI-related – were also strong risk factors for 
ACE-I/ARB discontinuation. Thiazide diuretic use was associated with lower risk, whereas loop 
diuretic use was associated with higher risk of discontinuation.  
Conclusion: In a real-world cohort, discontinuation of ACE-I/ARB was common, particularly in 
patients with lower eGFR. Hyperkalemia, hypotension, low bicarbonate level, and 
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hospitalization (AKI-related, in particular) were associated with higher risk of ACE-I/ARB 
discontinuation. Additional studies are needed to evaluate the risk-benefit balance of 
discontinuing ACE-I/ARB in the setting of CKD progression.  
Key words: discontinuation, antihypertensive, angiotensin converting enzyme inhibitors, 
angiotensin receptor blockers, chronic kidney disease, estimated glomerular filtration rate 
Abbreviations: ACE-I, angiotensin converting enzyme inhibitors; ACE-I/ARB, angiotensin 
converting enzyme inhibitors, angiotensin receptor blockers, or their combination; AKI, acute 
kidney injury; ARB, angiotensin receptor blockers; CI, confidence interval; CKD, chronic 
kidney disease; eGFR, estimated glomerular filtration rate; HR, hazard ratio; KDIGO guideline, 
Kidney Disease Improving Global Outcomes guideline; OR, odds ratio 
Introduction 
Angiotensin converting enzyme inhibitors (ACE-I) and angiotensin receptor blockers (ARB) are 
first-line antihypertensives for individuals with albuminuria, and are among the few clinically-
proven therapies to delay chronic kidney disease (CKD) progression in patients with 
albuminuria.
1–5
 ACE-Is and ARBs may also provide benefits post myocardial infarction, with 
improvement in myocardial performance and survival compared with placebo.
6–11
 On the other 
hand, ACE-Is, ARBs, or their combination (ACE-I/ARB) may predispose to hyperkalemia and 
acute kidney injury (AKI), risks that are particularly high among patients with low estimated 
glomerular filtration rate (eGFR) or albuminuria.
12,13
  
Currently, there is equipoise in the safety and efficacy of ACE-I/ARB use in advanced 
CKD, which motivated ongoing clinical trials such as the STOP-ACEi trial.
14,15
 The STOP-ACEi 
trial is a multi-center randomized controlled trial, which randomizes users of ACE-I/ARB with 
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advanced progressive CKD to either discontinue or continue to receive ACE-I/ARB.
14,15
 Clinical 
guidelines reflect the uncertainty, and remain vague as to when ACE-I/ARB needs to be 
discontinued in patients with advanced CKD, leaving providers and patients to navigate these 
questions without clear scientific guidance. For example, the Kidney Disease Improving Global 
Outcomes (KDIGO) guideline recommends “temporary discontinuation” of ACE-I/ARB “in 
people with a GFR <60 ml/min/1.73 m
2
 (GFR categories G3a-G5) who have serious intercurrent 
illness that increases the risk of AKI”; yet also states “do not routinely discontinue [ACE-I/ARB 
therapy] in people with GFR <30 ml/min/1.73 m
2
 as they remain nephroprotective”.
16
 Although 
clinical trials suggest the rate of discontinuation of ACE-Is and ARBs is low,
17
 less is known 
about real-world practice in the setting of CKD progression. 
The goal of this study was to describe ACE-I/ARB discontinuation patterns in a real-
world setting using over ten years of data from a large, integrated healthcare delivery network, 
with a particular focus on patterns in the setting of CKD. As a secondary objective, we identified 
additional factors associated with ACE-I/ARB discontinuation, hypothesizing that hypotension, 
elevated potassium levels, low bicarbonate level, and recent AKI-related hospitalization would 
be among the strongest risk factors for discontinuing ACE-I/ARB therapy. Additionally, we 
assessed how ACE-I/ARB discontinuation was affected by concurrent use of loop and thiazide 
diuretics, two medication classes known to be associated with decreased risk of hyperkalemia.
18
 
Finally, among discontinued users, we assessed antecedent events as well as the frequency of 
restarting ACE-I/ARB within six months of therapy discontinuation.    
Methods 
Study design, population, and data source 
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We conducted a retrospective study using electronic health records (EHR) data from a 
community-based cohort receiving primary care in the Geisinger Health System. Geisinger 
Health System has 12 hospitals in central and northeastern Pennsylvania. This large, integrated 
EHR database combines patient-level information on demographic characteristics, outpatient 
prescriptions, problem lists, inpatient and outpatient encounters, and laboratory test results. 
Based on prescription records, we identified individuals who were first prescribed an ACE-I, an 
ARB, or the combination of both between January 1, 2004 and December 31, 2015 
(Supplemental eTable 1). Baseline for each patient was the date of the initial ACE-I/ARB 
prescription, and follow-up was available until January 2017. Further inclusion criteria were age 
18 years or older; having an outpatient measurement of serum creatinine, potassium, bicarbonate 
level, and systolic blood pressure within one year before baseline; and having baseline eGFR 
≥15 mL/min/1.73 m
2
 and no previous diagnosis of end-stage renal disease. 
Outcome, exposure, and covariate definitions 
The primary outcome was discontinuation after starting ACE-I/ARB therapy. Discontinuation 
was defined as a gap in therapy greater than 60 days. Switching to different medications within 
ACE-I, ARB, or between the two medication classes was not considered as discontinuation. 
Specifically, we classified discontinuation as the end date of a prescription if there was no 
subsequent prescription within 60 days and the individual continued to receive follow-up in the 
Geisinger system. We censored patients at the therapy end date if no subsequent outpatient 
encounter was observed more than 60 days after the end date.  
CKD stage was defined based on the KDIGO guideline, with an eGFR  90, 60-89, 45-59, 
30-44, 15-29, and  15 mL/min/1.73 m2 classified as G1, G2, G3a, G3b, G4, and G5, 
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 The eGFR was estimated from outpatient serum creatinine levels using the CKD-
EPI equation.
19
 Baseline eGFR was the latest outpatient measure taken within one year prior to 
the initial ACE-I/ARB prescription. Time-dependent CKD stage was ascertained using time-
updated outpatient measures of serum creatinine.  
Other covariates included age at baseline, gender, race, initial class of therapy (i.e., ACE-
I, ARB, or the combination of both), and calendar year of initial ACE-I/ARB prescription. 
Additionally, we defined both baseline and time-dependent variables for serum potassium, 
bicarbonate level, and systolic blood pressure using the latest outpatient measurement during the 
one-year period prior to initial ACE-I/ARB prescription and updated outpatient measures during 
the follow-up period, respectively. We also captured baseline and time-updated use of loop and 
thiazide diuretics using prescription records (Supplemental eTable 1). Baseline comorbidities 
such as diabetes, congestive heart failure, and coronary artery disease were determined based on 
the presence of diagnostic codes prior to the initial prescription (Supplemental eTable 2). A 
binary variable was created to indicate “albuminuria testing”, defined by whether a patient had 
an outpatient measure of albuminuria on or before the baseline date. We also defined a time-
dependent “recent hospitalization” variable indicating hospitalization within the previous 30 days. 
For each hospitalization, we further classified it as AKI-related versus non-AKI-related based on 
diagnostic codes.   
Statistical analysis 
We described the baseline characteristics of the overall study cohort as well as stratified by 
baseline CKD stage. Cumulative incidence curves were used to depict time to discontinuation 
since initial ACE-I/ARB prescription by baseline CKD stage, accounting for the competing risk 
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of death. Fine-Gray competing risk regression models were constructed to quantify the 
associations of ACE-I/ARB discontinuation with CKD stage as well as other factors that may 
affect discontinuation, with death as a competing event.
20
 We first ran a model (Model 1) that 
included the following baseline variables: CKD stage, drug class/classes of the initial 
prescription (ACE-I, ARB, the combination of ACE-I and ARB,), calendar year of initial 
prescription (2004-2007, 2008-2011, 2012-2015), age (18-44, 45-64, 65+), female sex, black 
race, diabetes, congestive heart failure, coronary artery disease, albuminuria testing, potassium 
level ( 3.5, 3.5-5, 5-5.3,  5.3 mEq/L), systolic blood pressure ( 90, 90-140,  140 mmHg), low 
bicarbonate level ( 22 mmol/L), use of loop diuretics, and thiazide diuretics. Model 2 included 
the same variables except that CKD stage, potassium level, systolic blood pressure, low 
bicarbonate level, and use of loop and thiazide diuretics were captured as time-dependent 
variables to incorporate changes during the observation period. Model 2 also adjusted for the 
time-dependent variable of recent hospitalization status (no hospitalization, AKI-related 
hospitalization, non-AKI-related hospitalization within the previous 30 days).  
Among discontinued users, we described the prevalence of the following risk factors 
preceding discontinuation: CKD progression (decline in eGFR ≥30% compared to the antecedent 
measure), hyperkalemia (serum potassium >5 mEq/L), recent hospitalizations with and without 
AKI, bicarbonate level <22 mmol/L, and systolic blood pressure ≤90 mmHg, stratified by CKD 
stage prior to discontinuation. We performed logistic regression to assess the associations of 
demographic and clinical characteristics with restarting therapy within six months of 
discontinuation. 
Sensitivity analysis 
 ACE Inhibitors and ARBs in the Setting of Chronic Kidney Disease  
Thesis Dissertation | Yao Qiao 
 43 
We performed several sensitivity analyses. First, we defined discontinuation as a gap greater 
than 90 days without receiving ACE-I/ARB, and repeated the primary analyses. Second, we 
excluded individuals who were prescribed ACE-I/ARB at their first outpatient encounter in the 
Geisinger system. Finally, we evaluated the pattern of discontinuation across CKD stages of a 
comparison medication class, beta-blockers, to discern whether the observed associations were 
class-specific and not simply a marker of poor health. 
Results 
Study population 
A total of 53,912 individuals from the Geisinger Health System met the inclusion criteria 
(Figure 3-S 1). The study population was 50.6% female and had a mean (SD) age of 59.9 (14.9) 
years. The majority (88.0%) of the initial prescriptions were for ACE-I, with 11.3% for ARB, 
and 0.7% for both (Table 3-1). At baseline, 23,069 (42.8%), 23,158 (43.0%), 5,123 (9.5%), 
2,029 (3.8%), and 533 (1.0%) patients were classified as G1, G2, G3a, G3b, and G4 CKD stage, 
respectively. The proportion of patients initially prescribed ARBs was higher among those with 
more advanced baseline CKD stages.  
Association between discontinuation and the severity of CKD 
In total, 28,670 patients discontinued ACE-I/ARB therapy during follow-up. More advanced 
CKD stage at baseline was associated with greater risk of discontinuation (Figure 3-1; P<.001 
for all comparisons between G2, G3a, G3b, G4, and G1). Based on the cumulative incidence of 
ACE-I/ARB discontinuation accounting for the competing risk of death, we estimated that 20.7% 
[95% confidence interval (CI): 20.2-21.3%], 22.9% [95% CI: 22.3-23.4%], 26.7% [95% CI: 
25.4-27.9%], 30.1% [95% CI: 28.1-32.3%], and 45.3% [95% CI: 41.0-49.8%] had discontinued 
 ACE Inhibitors and ARBs in the Setting of Chronic Kidney Disease  
Thesis Dissertation | Yao Qiao 
 44 
ACE-I/ARB use by one year of therapy initiation among patients with G1, G2, G3a, G3b, and 
G4 CKD stage at baseline, respectively. These proportions rose to 46.8% [95% CI: 46.1-47.5%], 
49.7% [95% CI: 49.0-50.4%], 58.8% [95% CI: 57.2-60.3%], 68.4% [95% CI: 65.9-70.8%], and 
83.7% [95% CI: 79.5-87.4%] by five years after treatment initiation.  
In adjusted analysis, more advanced CKD stage at baseline continued to be significantly 
associated with higher risk of discontinuation (hazard ratio (HR): 1.06 [95% CI: 1.03-1.09], 1.22 
[95% CI: 1.17-1.28], 1.40 [95% CI: 1.32-1.49], and 2.09 [95% CI: 1.87-2.34] respectively for G2, 
G3a, G3b, and G4, compared with G1) (Model 1, Table 3-2). When CKD stage was treated as 
time-dependent, a similar pattern persisted but the effects were more pronounced, i.e. G2, G3a, 
G3b, and G4 yielded HRs of 1.08 [95% CI: 1.04, 1.11], 1.25 [95% CI: 1.19, 1.30], 1.45 [95% CI: 
1.36, 1.55], and 2.43 [95% CI: 2.17, 2.72], respectively, compared with G1 (Model 2). Although 
we excluded patients with G5 CKD stage at baseline, some patients progressed to G5 during 
follow up, which was associated with a substantially elevated risk of discontinuation (HR: 4.62 
[95% CI: 3.27, 6.52], compared with G1).  
Other factors associated with discontinuation 
AKI-related hospitalization was among the strongest risk factors of ACE-I/ARB discontinuation 
(HR: 7.10 [95% CI: 6.11-8.25]); non-AKI-related hospitalization also elevated the risk of 
discontinuation (HR: 4.54 [95% CI: 4.22-4.89]). High potassium levels (5-5.3, and >5.3 mEq/L) 
were associated with higher risk of discontinuation compared with potassium levels in the 
normal range (3.5-5 mEq/L). Similarly, low systolic blood pressure ( 90 mmHg) and low 
bicarbonate level ( 22 mmol/L) were risk factors for discontinuation. Concurrent use of thiazide 
diuretics was associated with decreased risk of ACE-I/ARB discontinuation whereas loop 
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diuretics were associated with increased risk of discontinuation. There was no difference in risk 
of discontinuation between patients with an initial prescription of ACE-I and those initially 
prescribed ARB.  
Events preceding discontinuation and restarting therapy within six months of discontinuation  
Among the 28,670 patients who discontinued ACE-I/ARB use, the proportion with antecedent 
CKD progression, hyperkalemia, recent hospitalizations with and without AKI, bicarbonate level 
<22 mmol/L, and systolic blood pressure ≤90 mmHg increased from G1 to G5 (Figure 3-2). 
Most patients who discontinued ACE-I/ARB at G1 or G2 stage did not manifest any of these risk 
factors before discontinuation; whereas the majority who discontinued at G4 or G5 stage 
experienced at least one of these risk factors prior to discontinuation.  
There were 6,135 (21.4%) patients who restarted ACE-I/ARB within six months of 
discontinuation, and 632 (2.2%) patients who died within six months of discontinuation without 
restarting therapy. Patients who discontinued at G3a were more likely to restart ACE-I/ARB 
within 6 months of discontinuation (odds ratio (OR): 1.18 [95% CI: 1.07, 1.31]) whereas those 
who discontinued at G4 or G5 were less likely to restart (OR: 0.83 [95% CI: 0.69, 0.99]), 
compared with G1 (Table 3-S 3). No significant differences were detected between G1 and other 
G-stages. Patients who discontinued after a recent non-AKI-related hospitalization were more 
likely to restart therapy. Additionally, women were less likely to restart than men. 
Sensitivity analysis 
The sensitivity analyses using a 90-day gap as the threshold to define discontinuation and 
excluding individuals prescribed ACE-I/ARB at the first outpatient encounter yielded 
substantively similar findings. 
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Among 44,634 incident users of beta-blockers, there was a completely different pattern of 
time to discontinuation across CKD stages in comparison to ACE-I/ARB, with G1 stage showing 
the highest rate of discontinuation and other CKD stages showing fairly similar rates of 
discontinuation (Figure 3-S 2).  
This study was approved by the Johns Hopkins University Institutional Review Board and the 
Geisinger Medical Center Institutional Review Board.  
Discussion 
Main findings 
In this study of 53,912 incident users of ACE-I/ARB observed over a decade in a community-
based health system, we estimated that the majority had a discontinuation in treatment by 5 years. 
There was no difference in risk of discontinuation between people initially prescribed an ACE-I 
compared to those prescribed an ARB, but there were strong associations of advanced CKD 
stages with therapy discontinuation, with patients with G4 disease (eGFR: 15-29 ml/min/1.73 m
2
) 
more than twice as likely to discontinue therapy compared to people with eGFR  90 
mL/min/1.73m
2
. This pattern was specific to ACE-I and ARB therapy and not observed in 
incident beta-blocker users. We also observed that recent hospitalization, particularly 
hospitalization with AKI, was a strong risk factor for discontinuation. Our findings highlight 
how commonly ACE-Is and ARBs are discontinued among individuals with CKD, and suggest 
that post-hospitalization periods are critical junctures to re-evaluate appropriate ACE-I and ARB 
use. Given the associations with acidosis and thiazide diuretics, we propose that correcting 
acidosis and treating with thiazide diuretics may provide an opportunity to extend the duration of 
ACE-I/ARB therapy, although this requires formal testing.  
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Discontinuation of treatment has been relatively understudied compared to the initiation 
and escalation of a given therapy. Among patients with CKD, the risk of treatment 
discontinuation or treatment withholding may be particularly high. For example, the utilization 
of coronary angiography is lower in patients with CKD compared to those without, which may 
be due to perceived uncertainties of the procedure’s risks and benefits in the CKD 
population.
21,22
 A previous study showed that patients who initiated ACE-I/ARB therapy for 
renal indications were more likely to discontinue therapy than those who initiated ACE-I/ARB 
therapy for other indications.
23
 Although our study cannot tease out the reason for ACE-I/ARB 
prescription, it does suggest that patients with lower GFR take therapy for shorter amounts of 
time, which may diminish the beneficial effects of ACE-I/ARB use in CKD. Indeed, the KDIGO 
guideline does not recommend routine discontinuation of ACE-I and ARB in patients with GFR 




 It is also worth noting that our study only revealed the pattern among 
individuals who initiated ACE-I/ARB; there are many patients with CKD who would benefit 
from ACE-I/ARB use but never initiated the therapy. 
Our results expand upon existing data on ACE-I and ARB discontinuation rates, which 
largely originated from clinical trials.
24
 A meta-analysis of 22,542 patients without heart failure 
across eight randomized controlled trials showed a pooled discontinuation rate of 6.5% and 4.9% 
for ACE-I and ARB users, respectively, over an average of 3.4 years of follow-up.
17
 In 
comparison, our study reflected real-world ACE-I/ARB use, had a greater representation of 
patients with advanced CKD, and observed a much higher rate of discontinuation, with over 50% 
ACE-I/ARB users discontinuing therapy by 5 years. Our discontinuation rate was consistent with 
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An interesting finding in our study was that thiazide diuretics were associated with lower 
risk of ACE-I/ARB discontinuation. In contrast, loop diuretics were associated with higher risk 
of discontinuation. This may be due to the fact that thiazide diuretics have greater effect on 
lowering serum potassium than loop diuretics, thus preventing hyperkalemia;
25–30
 whereas loop 
diuretics may result in greater water diuresis, predisposing to AKI. We also found that lower 
bicarbonate level was a risk factor for ACE-I/ARB discontinuation. These results provide 
important insights for clinical practice, suggesting that thiazide diuretics and/or correction of 
metabolic acidosis may prolong the safe use of ACE-I/ARB. On the other hand, the associations 
may simply reflect the sicker patient population that develops metabolic acidosis and requires 
loop diuretics.  
There are several limitations to our study. First, our study population was primarily white, 
limiting generalizability to other races/ethnicities. Second, ACE-I/ARB use was ascertained 
using prescription data and we did not validate whether these medications were actually 
dispensed or taken. Thus, our study demonstrates prescription patterns in clinical practice rather 
than patient adherence to medication. Finally, we do not know the reason a medication was 
discontinued, and patterns cannot be interpreted as causal.  
Strengths of our study included the large community-based cohort with over a decade of 
follow-up, which provided sufficient power and a high level of precision in study results. 
Clinical measures were ascertained not only at baseline, but also throughout the follow-up period. 
We demonstrated robustness of our findings through multiple sensitivity analyses including 
using a more conservative threshold of medication discontinuation, and comparing patterns to a 
negative control class of medications. 
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Conclusion 
In conclusion, among 53,912 incident users of ACE-I/ARB in a large community-based cohort, 
over half discontinued therapy within 5 years, with higher risks of discontinuation among those 
with more advanced CKD. Risk of discontinuation was particularly high subsequent to AKI-
related hospitalization. Use of thiazide diuretics was associated with a lower risk of ACE-I/ARB 
discontinuation whereas loop diuretics were associated with a higher risk of discontinuation. Our 
findings suggest a need for more precise assessment of risk-benefit balance of ACE-I/ARB 
discontinuation in patients with advanced CKD, as both overuse and underuse can be harmful to 
health outcomes. 
References 
1.  Whelton PK, Carey RM, Aronow WS, et al. 2017 
ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the 
Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A 
Report of the American College of Cardiology/American Heart Association Task Force on 
Clinical Practice Guidelines. J Am Coll Cardiol. 2018;71(19):e127-e248. 
doi:10.1016/j.jacc.2017.11.006 
2.  Marin R, Ruilope LM, Aljama P, et al. A random comparison of fosinopril and nifedipine 
GITS in patients with primary renal disease. J Hypertens. 2001;19(10):1871-1876. 
3.  Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-
receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J 
Med. 2001;345(12):851-860. doi:10.1056/NEJMoa011303 
 ACE Inhibitors and ARBs in the Setting of Chronic Kidney Disease  
Thesis Dissertation | Yao Qiao 
 50 
4.  Qin Y, Chen T, Chen Q, et al. The effect of angiotensin-converting enzyme 
inhibitor/angiotensin receptor blocker use on mortality in patients with chronic kidney 
disease: a meta-analysis of observational studies. Pharmacoepidemiol Drug Saf. 
2016;25(5):503-511. doi:10.1002/pds.3941 
5.  Agodoa LY, Appel L, Bakris GL, et al. Effect of ramipril vs amlodipine on renal outcomes 
in hypertensive nephrosclerosis: a randomized controlled trial. JAMA. 2001;285(21):2719-
2728. 
6.  Borghi C, Omboni S, Novo S, Vinereanu D, Ambrosio G, Ambrosioni E. Efficacy and 
Safety of Zofenopril Versus Ramipril in the Treatment of Myocardial Infarction and Heart 
Failure: A Review of the Published and Unpublished Data of the Randomized Double-
Blind SMILE-4 Study. Adv Ther. 2018;35(5):604-618. doi:10.1007/s12325-018-0697-x 
7.  Ambrosioni E, Borghi C, Magnani B. The effect of the angiotensin-converting-enzyme 
inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The 
Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. N 
Engl J Med. 1995;332(2):80-85. doi:10.1056/NEJM199501123320203 
8.  Borghi C, Ambrosioni E, Survival of Myocardial Infarction Long-term Evaluation Study 
Group. Effects of zofenopril on myocardial ischemia in post-myocardial infarction patients 
with preserved left ventricular function: the Survival of Myocardial Infarction Long-term 
Evaluation (SMILE)-ISCHEMIA study. Am Heart J. 2007;153(3):445.e7-14. 
doi:10.1016/j.ahj.2006.12.005 
 ACE Inhibitors and ARBs in the Setting of Chronic Kidney Disease  
Thesis Dissertation | Yao Qiao 
 51 
9.  Domanski MJ, Exner DV, Borkowf CB, Geller NL, Rosenberg Y, Pfeffer MA. Effect of 
angiotensin converting enzyme inhibition on sudden cardiac death in patients following 
acute myocardial infarction. A meta-analysis of randomized clinical trials. J Am Coll 
Cardiol. 1999;33(3):598-604. 
10.  Pfeffer MA, Braunwald E, Moyé LA, et al. Effect of captopril on mortality and morbidity in 
patients with left ventricular dysfunction after myocardial infarction. Results of the survival 
and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 
1992;327(10):669-677. doi:10.1056/NEJM199209033271001 
11.  Pfeffer MA, McMurray JJV, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial 
infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 
2003;349(20):1893-1906. doi:10.1056/NEJMoa032292 
12.  Tomlinson LA, Abel GA, Chaudhry AN, et al. ACE inhibitor and angiotensin receptor-II 
antagonist prescribing and hospital admissions with acute kidney injury: a longitudinal 
ecological study. PloS One. 2013;8(11):e78465. doi:10.1371/journal.pone.0078465 
13.  Ahuja TS, Freeman D, Mahnken JD, Agraharkar M, Siddiqui M, Memon A. Predictors of 
the development of hyperkalemia in patients using angiotensin-converting enzyme 
inhibitors. Am J Nephrol. 2000;20(4):268-272. doi:10.1159/000013599 
14.  Ahmed A, Jorna T, Bhandari S. Should We STOP Angiotensin Converting Enzyme 
Inhibitors/Angiotensin Receptor Blockers in Advanced Kidney Disease? Nephron. 
2016;133(3):147-158. doi:10.1159/000447068 
 ACE Inhibitors and ARBs in the Setting of Chronic Kidney Disease  
Thesis Dissertation | Yao Qiao 
 52 
15.  Bhandari S, Ives N, Brettell EA, et al. Multicentre randomized controlled trial of 
angiotensin-converting enzyme inhibitor/angiotensin receptor blocker withdrawal in 
advanced renal disease: the STOP-ACEi trial. Nephrol Dial Transplant. 2016;31(2):255-
261. doi:10.1093/ndt/gfv346 
16.  National Kidney Foundation. KDIGO 2012 Clinical Practice Guideline for the Evaluation 
and Management of Chronic Kidney Disease. 2013. 
http://www.kdigo.org/clinical_practice_guidelines/pdf/CKD/KDIGO_2012_CKD_GL.pdf. 
17.  Bangalore S, Fakheri R, Toklu B, Ogedegbe G, Weintraub H, Messerli FH. Angiotensin-
Converting Enzyme Inhibitors or Angiotensin Receptor Blockers in Patients Without Heart 
Failure? Insights From 254,301 Patients From Randomized Trials. Mayo Clin Proc. 
2016;91(1):51-60. doi:10.1016/j.mayocp.2015.10.019 
18.  Chang AR, Sang Y, Leddy J, et al. Antihypertensive Medications and the Prevalence of 
Hyperkalemia in a Large Health System. Hypertens Dallas Tex 1979. 2016;67(6):1181-
1188. doi:10.1161/HYPERTENSIONAHA.116.07363 
19.  Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration 
rate. Ann Intern Med. 2009;150(9):604-612. 
20.  Fine JP, Gray RJ. A Proportional Hazards Model for the Subdistribution of a Competing 
Risk. J Am Stat Assoc. 1999;94(446):496-509. doi:10.1080/01621459.1999.10474144 
21.  Chertow GM, Normand S-LT, McNeil BJ. “Renalism”: inappropriately low rates of 
coronary angiography in elderly individuals with renal insufficiency. J Am Soc Nephrol 
JASN. 2004;15(9):2462-2468. doi:10.1097/01.ASN.0000135969.33773.0B 
 ACE Inhibitors and ARBs in the Setting of Chronic Kidney Disease  
Thesis Dissertation | Yao Qiao 
 53 
22.  Weisbord SD. AKI and medical care after coronary angiography: renalism revisited. Clin J 
Am Soc Nephrol CJASN. 2014;9(11):1823-1825. doi:10.2215/CJN.09430914 
23.  Mahmoudpour SH, Asselbergs FW, Souverein PC, de Boer A, Maitland-van der Zee AH. 
Prescription patterns of angiotensin-converting enzyme inhibitors for various indications: A 
UK population-based study. Br J Clin Pharmacol. June 2018. doi:10.1111/bcp.13692 
24.  Messerli FH, Bangalore S, Bavishi C, Rimoldi SF. Angiotensin-Converting Enzyme 
Inhibitors in Hypertension: To Use or Not to Use? J Am Coll Cardiol. 2018;71(13):1474-
1482. doi:10.1016/j.jacc.2018.01.058 
25.  Moser M. The diuretic dilemma and the management of mild hypertension. J Clin 
Hypertens. 1986;2(2):195-202. 
26.  Mukete BN, Rosendorff C. Effects of low-dose thiazide diuretics on fasting plasma glucose 
and serum potassium-a meta-analysis. J Am Soc Hypertens JASH. 2013;7(6):454-466. 
doi:10.1016/j.jash.2013.05.004 
27.  Roush GC, Sica DA. Diuretics for Hypertension: A Review and Update. Am J Hypertens. 
2016;29(10):1130-1137. doi:10.1093/ajh/hpw030 
28.  Savage PJ, Pressel SL, Curb JD, et al. Influence of long-term, low-dose, diuretic-based, 
antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and 
women with isolated systolic hypertension: The Systolic Hypertension in the Elderly 
Program. SHEP Cooperative Research Group. Arch Intern Med. 1998;158(7):741-751. 
 ACE Inhibitors and ARBs in the Setting of Chronic Kidney Disease  
Thesis Dissertation | Yao Qiao 
 54 
29.  Roush GC, Ernst ME, Kostis JB, Tandon S, Sica DA. Head-to-head comparisons of 
hydrochlorothiazide with indapamide and chlorthalidone: antihypertensive and metabolic 
effects. Hypertens Dallas Tex 1979. 2015;65(5):1041-1046. 
doi:10.1161/HYPERTENSIONAHA.114.05021 
30.  Tannen RL. Diuretic-induced hypokalemia. Kidney Int. 1985;28(6):988-1000. 
 ACE Inhibitors and ARBs in the Setting of Chronic Kidney Disease  
Thesis Dissertation | Yao Qiao 
 55 
Figure 3- 1. Discontinuation of ACE-I/ARB among incident users, by CKD stage at baseline 
Abbreviations: ACE-I/ARB, angiotensin converting enzyme inhibitors, angiotensin receptor 
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Figure 3- 2. Events preceding discontinuation of ACE-I/ARB, by CKD stage 
 
Abbreviations: ACE-I/ARB, angiotensin converting enzyme inhibitors, angiotensin receptor 
blockers, or their combination; CKD, chronic kidney disease; AKI, acute kidney injury 
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Table 3- 1. Baseline characteristics of incident users of ACE-I/ARB by baseline CKD stage in the Geisinger health system, N (%)
a
 
CKD Stage at treatment initiation 













      
ACE-I  47472 (88.0) 20906 (90.6) 20314 (87.7) 4296 (83.9) 1594 (78.6) 362 (67.9) 
ARB  6068 (11.3) 2021 (8.8) 2703 (11.7) 784 (15.3) 408 (20.1) 152 (28.5) 
ACE-I and ARB 372 (0.7) 142 (0.6) 141 (0.6) 43 (0.8) 27 (1.3) 19 (3.6) 
Calendar year 
      
2004-2007 18103 (33.6) 6834 (29.6) 8094 (35.0) 2078 (40.6) 867 (42.7) 230 (43.2) 
2008-2011 18504 (34.3) 8448 (36.6) 7681 (33.2) 1552 (30.3) 638 (31.4) 185 (34.7) 
2012-2015 17305 (32.1) 7787 (33.8) 7383 (31.9) 1493 (29.1) 524 (25.8) 118 (22.1) 
Age group 
      
18-44 8347 (15.5) 6939 (30.1) 1232 (5.3) 102 (2.0) 44 (2.2) 30 (5.6) 
45-64 24580 (45.6) 13437 (58.3) 9819 (42.4) 937 (18.3) 284 (14.0) 103 (19.3) 
65+ 20985 (38.9) 2693 (11.7) 12107 (52.3) 4084 (79.7) 1701 (83.8) 400 (75.1) 
Female 27256 (50.6) 10846 (47.0) 11822 (51.1) 3031 (59.2) 1268 (62.5) 289 (54.2) 
Black race 1319 (2.5) 893 (3.9) 343 (1.5) 57 (1.1) 15 (0.7) 11 (2.1) 
Diabetes 16641 (30.9) 7798 (33.8) 6245 (27.0) 1594 (31.1) 776 (38.3) 228 (42.8) 
Congestive heart failure 3991 (7.4) 791 (3.4) 1768 (7.6) 794 (15.5) 488 (24.1) 150 (28.1) 
Coronary artery disease 9823 (18.2) 2530 (11.0) 4795 (20.7) 1533 (29.9) 772 (38.1) 193 (36.2) 
Measured albuminuria 14222 (26.4) 6692 (29.0) 5420 (23.4) 1384 (27.0) 577 (28.4) 149 (28.0) 
Potassium level 
      
3.5 mEq/L or lower 2039 (3.8) 918 (4.0) 844 (3.6) 193 (3.8) 68 (3.4) 16 (3.0) 
3.5-5 mEq/L 49764 (92.3) 21573 (93.5) 21449 (92.6) 4608 (90.0) 1726 (85.1) 408 (76.6) 
5-5.3 mEq/L 1573 (2.9) 460 (2.0) 674 (2.9) 219 (4.3) 158 (7.8) 62 (11.6) 
Above 5.3 mEq/L 536 (1.0) 118 (0.5) 191 (0.8) 103 (2.0) 77 (3.8) 47 (8.8) 
Systolic blood pressure  
      
90 mmHg or lower 221 (0.4) 67 (0.3) 76 (0.3) 42 (0.8) 26 (1.3) 10 (1.9) 
90-140 mmHg 24370 (45.2) 10388 (45.0) 10015 (43.3) 2562 (50.0) 1126 (55.5) 279 (52.4) 
140 mmHg or above 29321 (54.4) 12614 (54.7) 13067 (56.4) 2519 (49.2) 877 (43.2) 244 (45.8) 
Bicarbonate lower than 22mmol/L 1022 (1.9) 456 (2.0) 290 (1.3) 101 (2.0) 89 (4.4) 86 (16.1) 
Loop diuretic use  6016 (11.2) 1509 (6.5) 2570 (11.1) 1083 (21.1) 641 (31.6) 213 (40.0) 
Thiazide diuretic use 14343 (26.6) 6059 (26.3) 6383 (27.6) 1311 (25.6) 457 (22.5) 133 (25.0) 
a
ACE-I = angiotensin converting enzyme inhibitors; ACE-I/ARB = angiotensin converting enzyme inhibitors, angiotensin receptor 
blockers, or their combination; ARB = angiotensin receptor blockers; CKD = chronic kidney disease
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Table 3- 2. Association of demographic and clinical factors with discontinuation of 
ACE-I/ARB, subhazard ratio and 95% confidence interval
a,b
 
Demographic and Clinical Factors Model 1 Model 2 
CKD stage (referent: G1) 
  G2 1.06 (1.03, 1.09) 1.08 (1.04, 1.11) 
G3a 1.22 (1.17, 1.28) 1.25 (1.19, 1.30) 
G3b 1.40 (1.32, 1.49) 1.45 (1.36, 1.55) 





4.62 (3.27, 6.52) 
Drug class (referent: ACE-I alone) 
  
ACE-I and ARB 0.95 (0.84, 1.08) 0.93 (0.80, 1.07) 
ARB alone 0.99 (0.95, 1.02) 0.99 (0.95, 1.03) 
Calendar year (referent: 2004-2007) 
  
2008-2011 1.14 (1.10, 1.17) 1.13 (1.09, 1.16) 
2012-2015 1.24 (1.20, 1.28) 1.20 (1.16, 1.24) 
Age group (referent: 18-44) 
  
45-64 0.82 (0.79, 0.85) 0.80 (0.77, 0.83) 
65+ 0.94 (0.90, 0.98) 0.82 (0.78, 0.85) 
Female 1.15 (1.13, 1.18) 1.15 (1.12, 1.18) 
Black race 1.07 (0.99, 1.16) 1.07 (0.99, 1.16) 
Diabetes  0.99 (0.96, 1.03) 0.94 (0.91, 0.98) 
Congestive heart failure  1.00 (0.95, 1.05) 0.79 (0.74, 0.84) 
Coronary artery disease  1.15 (1.11, 1.18) 1.07 (1.03, 1.10) 
Measured albuminuria  0.93 (0.89, 0.96) 0.96 (0.92, 0.99) 
Potassium level (referent: 3.5-5 
mEq/L)   
3.5 mEq/L or lower 1.04 (0.98, 1.11) 1.12 (1.03, 1.21) 
5-5.3 mEq/L 1.09 (1.02, 1.16) 1.06 (0.99, 1.14) 
Above 5.3 mEq/L 1.24 (1.11, 1.38) 1.94 (1.74, 2.17) 
Systolic blood pressure (referent: 90-
140 mmHg)   
90 mmHg or lower 1.23 (1.01, 1.49) 1.84 (1.57, 2.15) 
140 mmHg or above 0.93 (0.90, 0.95) 1.07 (1.04, 1.10) 
Bicarbonate lower than 22mmol/L 1.14 (1.05, 1.24) 1.11 (1.01, 1.22) 
Loop diuretic use  1.14 (1.09, 1.18) 1.34 (1.29, 1.39) 
Thiazide diuretic use 0.90 (0.88, 0.93) 0.85 (0.82, 0.87) 
Hospitalization status (referent: no 
hospitalization)   
Non-AKI-related - 4.54 (4.22, 4.89) 
AKI related - 7.10 (6.11, 8.25) 
a
 ACE-I = angiotensin converting enzyme inhibitors; ACE-I/ARB = angiotensin converting enzyme 
inhibitors, angiotensin receptor blockers, or their combination; AKI = acute kidney injury; ARB = 
angiotensin receptor blockers; CKD = chronic kidney disease; eGFR = estimated glomerular filtration 
rate. 
b
Shaded fields indicate time-dependent form of the corresponding variables. 
c
Patients with CKD 
G5 stage at baseline were excluded but some patients progressed to G5 after therapy initiation. 
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Supplement 
Table 3-S 1. Drug products included in the analysis 
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metoprolol 
metoprolol succinate 
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Table 3-S 2. International classification of disease, 9th and 10th editions, clinical 
modification (ICD-9-CM, ICD-10-CM) used to define disease conditions 
Disease Conditions ICD-9-CM codes ICD-10-CM codes 
Diabetes 250.x E10.x, E11.x, E13.x 
Congestive heart failure 428.x I50.x 
Coronary artery disease 
410.x, 411.0, 411.8x, 
412, 414.x, 36.1x  
I21.x, I22.x, I23.x, 
I24.x, I25.x 




Table 3-S 3. Associations between clinical and demographic factors and restarting ACE-
I/ARB within six months of therapy discontinuation
a
 
Demographic and Clinical Factors Odds Ratio (95% CI) 
CKD Stage (referent: G1) 
 G2 1.04 (0.96, 1.12) 
G3a 1.18 (1.07, 1.31) 
G3b 1.11 (0.97, 1.26) 
G4 or G5 0.83 (0.69, 0.99) 
Hospitalization (referent: no hospitalization) 
 Non-AKI-related 1.22 (1.09, 1.37) 
AKI-related 1.15 (0.97, 1.36) 
Hypotension 0.80 (0.62, 1.03) 
Low bicarbonate level 0.98 (0.83, 1.16) 
Progression 1.09 (0.92, 1.29) 
Hyperkalemia 1.07 (0.96, 1.20) 
Age group (referent: 18-44) 
 45-64 1.20 (1.10, 1.31) 
65+ 1.13 (1.02, 1.25) 
Female 0.92 (0.87, 0.97) 
Black race 1.20 (1.00, 1.44) 
 
a
ACE-I/ARB = angiotensin converting enzyme inhibitors, angiotensin receptor blockers, 





Figure 3-S 1. Derivation of study cohort 
 
Abbreviations: ACE-I/ARB, angiotensin converting enzyme inhibitors, angiotensin 
receptor blockers, or their combination; CKD, chronic kidney disease; eGFR, estimated 
glomerular filtration rate 
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Figure 3-S 2. Time to discontinuation of beta-blockers since therapy initiation, by 
baseline CKD stage 
 





Chapter 4. Association Between Renin-angiotensin System 
Blockade Discontinuation And All-cause Mortality Among 
People With Low Estimated Glomerular Filtration Rate 
Abstract 
IMPORTANCE: It is uncertain whether and when angiotensin-converting enzyme 
inhibitors (ACE-I) and angiotensin II receptor blockers (ARB) should be discontinued in 
individuals with low estimated glomerular filtration rate (eGFR). 
OBJECTIVE: To investigate the association of ACE-I/ARB discontinuation after eGFR 
declines to below 30 ml/min/1.73m
2
 with the risk of mortality, major adverse 
cardiovascular events (MACE), and end-stage kidney disease (ESKD).  
DESIGN: Retrospective, propensity-score matched cohort study.  
SETTING: An integrated health care system serving rural areas of central and 
northeastern Pennsylvania. 
PARTICIPANTS: 3909 adults who initiated ACE-I/ARB between 2004 and 2018 and 
had an eGFR decline to below 30 ml/min/1.73m
2
 during treatment, with follow up until 
January 25, 2019. 
EXPOSURES: Individuals were classified based on whether they discontinued ACE-
I/ARB within six months after the eGFR decline to below 30 ml/min/1.73m
2
.  
MAIN OUTCOMES AND MEASURES: We assessed the association between ACE-
I/ARB discontinuation and mortality over the subsequent five years using multivariable 
Cox proportional hazards regression models, adjusting for patient characteristics at the 
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time of the eGFR decline in a propensity-score matched sample. Secondary outcomes 
included MACE and ESKD.  
RESULTS: Of the 3909 ACE-I/ARB users with an eGFR decline to below 30 
ml/min/1.73m
2
, 2406 (62%) were female and the mean (SD) age was 73.7 (12.6) years. 
There were 1235 individuals who discontinued ACE-I/ARB within six months after 
eGFR decline and 2674 individuals who did not. A total of 434 (35.1%) and 786 (29.4%) 
individuals died over a median follow-up of 2.9 years among those with and without 
ACE-I/ARB discontinuation, respectively. In the propensity-score matched sample of 
2410 individuals, ACE-I/ARB discontinuation was associated with a higher risk of 
mortality (HR: 1.39 [95% CI: 1.20-1.60]) and MACE (HR: 1.37 [95% CI: 1.20-1.56]), 
but no statistically significant difference in the risk of ESKD (HR: 1.19 [95% CI: 0.86-
1.65]). 
CONCLUSIONS AND RELEVANCE: Our findings provide evidence that continuing 
ACE-I/ARB in patients with declining kidney function may provide cardiovascular 
benefit without excessive harm of ESKD.  
Introduction  
Angiotensin-converting enzyme inhibitors (ACE-I) and angiotensin II receptor blockers 
(ARB) are the mainstays of therapy for hypertension, albuminuric chronic kidney disease 
(CKD), heart failure with reduced ejection fraction, and coronary artery disease.
1–6
 
However, the potential benefits of ACE-I/ARB therapy must be weighed against the 
potential risks, which include acute, largely hemodynamic reductions in estimated 
glomerular filtration rates (eGFR), hyperkalemia, and acute kidney injury (AKI).
4,7,8
 The 
risks of these adverse events are particularly relevant in individuals with lower eGFR. In 
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real-world studies, over half of the individuals initiating ACE-I/ARB discontinued within 




The Kidney Disease Improving Global Outcomes (KDIGO) guidelines suggest 
“temporary discontinuation” of ACE-I/ARB in those with a GFR <60 ml/min/1.73m
2
 
(GFR categories G3a-G5) “who have serious intercurrent illness that increases the risk of 
AKI”; but also emphasize to “not routinely discontinue [ACE-I/ARB] in people with 
GFR <30 ml/min/1.73m
2
 as they remain nephroprotective”.
11
 Existing literature 
evaluating the risk-benefit of using ACE-I/ARB in individuals with advanced CKD is 
conflicting.
12–15
 The ongoing STOP-ACEi trial aims to evaluate the difference in 3-year 
eGFR, randomizing 410 ACE-I/ARB users with advanced CKD to either continue or 
discontinue ACE-I/ARB.
16
 However, the benefits of ACE-I/ARB therapy may also 
extend to cardiovascular disease and mortality.  
Using data from a large, integrated health system, we assessed the association of 
ACE-I/ARB discontinuation with the risk of all-cause mortality, major adverse 
cardiovascular events (MACE), and end-stage kidney disease (ESKD) among ACE-
I/ARB users whose eGFR dropped to below 30 ml/min/1.73m
2
. As a secondary objective, 
we evaluated the effect of ACE-I/ARB discontinuation among users who experienced a 
decline in eGFR by  40% within one year, a surrogate end point for kidney failure used 




Study setting and study population 
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We identified users of ACE-I/ARB from the Geisinger Health System, a fully integrated 
health care system that serves 45 counties in central and northeastern Pennsylvania. The 
local population has an estimated 1% annual outmigration rate.
18
 The electronic health 
records provide patient-level data on outpatient prescriptions, problem lists, laboratory 
test results, inpatient and outpatient encounters, and demographic characteristics.  
We first identified 162654 individuals who initiated ACE-I/ARB between year 
2004 and 2018. Next, we subset the population to the 10810 individuals whose outpatient 
eGFR declined to below 30 ml/min/1.73m
2 
after therapy initiation. Individuals who 
discontinued ACE-I/ARB before the initial drop to below 30 ml/min/1.73m
2 
were 
excluded (N=5402). A window of 6 months after the eGFR decline was constructed to 
assess ACE-I/ARB discontinuation; thus, in primary analysis, baseline date of follow-up, 
T0, was 6 months after the day of eGFR decline to a value <30 ml/min/1.73m
2
. 
Individuals who discontinued and restarted ACE-I/ARB therapy within the 6-month 
period before T0 (N=233) and those who did not meet our formal criteria for 
discontinuation but were off ACE-I/ARB at T0 (N=317) were excluded. Further exclusion 
criteria included T0 after the end of follow-up (N=214); the absence of serum potassium 
and systolic blood pressure measures in the year prior to the eGFR decline (N=303); <18 
years of age at the time of the eGFR decline (N=3); and death before T0 (N=324) or 
prevalent ESKD at T0 (N=105) (Figure 4-S 1). 
Treatment strategies under comparison 
We compared individuals who stopped ACE-I/ARB within 6 months after a decline in 
eGFR to below 30 ml/min/1.73m
2
 with those who did not. We defined discontinuation as 
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a gap in therapy longer than 60 days occurring before T0. We allowed for switching 
between ACE-I and ARB, or to different medications within each class, given evidence 
suggesting ACE-Is and ARBs share similar mechanisms, benefits, and risks.
4,5,11
  
Endpoints and follow-up 
The primary endpoint was mortality over the subsequent five years after T0. Secondary 
endpoints included MACE and ESKD. For all endpoints, follow-up was available up until 
January 25, 2019. MACE, defined as the first occurrence of death, myocardial infarction, 
percutaneous coronary intervention, or coronary artery bypass after T0, was ascertained 
using previously validated International Classification of Disease (ICD) procedure and 
diagnosis codes.
19
 ESKD was captured by linking to the United States Renal Data System, 
which was available up until July 31, 2018. For the remaining six months between this 
date and January 25, 2019, the ICD procedure and diagnosis codes of kidney transplant 
and dialysis were used to ascertain ESKD cases (Table 4-S 1).  
We investigated as additional outcomes hyperkalemia and AKI during follow-up. 
Hyperkalemia was defined as the first serum potassium level greater than 5.5 mEq/L 
occurring as an outpatient or as the first measure of an inpatient episode. AKI was 
obtained using the ICD diagnosis codes (Table 4-S 2). 
Baseline Covariates 
We defined baseline serum potassium level, systolic blood pressure, and serum creatinine 
as the most recent outpatient measure available within one year before the eGFR decline 
to below 30 ml/min/1.73m
2
. We used the CKD-EPI equation to estimate GFR based on 
outpatient serum creatinine level.
20
 Baseline comorbidities such as history of stroke, 
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congestive heart failure, diabetes, and coronary artery disease were defined based on the 
presence of the corresponding ICD codes. We also ascertained concurrent use of other 
medications such as statin, antiplatelet agents, and beta-blockers at the time of the eGFR 
decline, and whether a patient was hospitalized, had a nephrology visit, and the number 
of outpatient encounters during the one-year period prior to the eGFR decline. Other 
covariates included sex, race, age, and calendar year (categorized as 2004-2008, 2009-
2013, 2014-2019) at the time of the eGFR decline.  
Propensity-score matching  
We performed nearest-neighbor propensity-score matching without replacement to 1:1 
match individuals who discontinued ACE-I/ARB to those without discontinuation, using 
a caliper of 0.25 standard deviation of the propensity-score.
21
 Covariates in the 
propensity-score model included baseline variables defined above. We chose these 
variables a priori to minimize indication bias that might confound the association 
between ACE-I/ARB discontinuation and the outcome. Balance between the two 
comparison groups was evaluated using the standardized mean difference across 





We described baseline characteristics of the study population by treatment group both 
before and after propensity-score matching using proportions for categorical variables 
and means and standard deviations for continuous variables. We used Kaplan Meier 
curves to depict survival over five years after T0, stratified by treatment strategy. We then 
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assessed the association of ACE-I/ARB discontinuation with mortality using 
multivariable Cox proportional hazards regression analysis in the propensity-score 
matched sample, adjusting for all baseline covariates. We used linear spline forms of 
serum potassium with knots at 4 and 5 mEq/L, systolic blood pressure with knots at 90 
and 140 mmHg, and age with knots at 45 and 65 years, to allow for non-linear 
relationship. We applied similar methods to assess the associations of ACE-I/ARB 
discontinuation with MACE, ESKD, hyperkalemia, and AKI. In cumulative incidence 
curves for ESKD, we illustrated the proportion remaining free of ESKD accounting for 
the competing risk of death. 
We assessed whether the effect of ACE-I/ARB discontinuation differed by 
baseline diabetes, congestive heart failure, coronary artery disease, and history of stroke. 
We tested for potential effect modification by the presence of macroalbuminuria at 
baseline. Macroalbuminuria was defined as the latest measure within the three-year 
window before eGFR declined to below 30 ml/min/1.73m
2
 and urine albumin to 
creatinine ratio>300 mg/g; if not available, urine protein to creatinine ratio>700 mg/g or  
dipstick measure of “++” or greater were also accepted. 
To evaluate the association of ACE-I/ARB discontinuation following a  40% 
decline in eGFR within one year with the risks of mortality, MACE, and ESKD, we 
identified individuals who had a  40% decline in eGFR during treatment compared with 
the previous measure within a year. We repeated the primary analyses within this sample, 
with T0 defined as 6 months after the first time eGFR decreased by  40% during ACE-




To illustrate the observed associations between ACE-I/ARB discontinuation and the 
endpoints of interest were not due to different health status between the two treatment 
groups, we compared the risk of bleeding, an outcome believed to be not affected by 
ACE-I/ARB use, between the propensity-score matched treatment groups, adjusting for 
antiplatelet agent use at the time of the eGFR decline. Bleeding was ascertained from 
emergency department visits and hospitalization episodes using ICD diagnosis codes.  
Sensitivity analysis 
Several sensitivity analyses were performed. First, we estimated the association between 
ACE-I/ARB discontinuation and ESKD using the Fine-Gray competing risk regression 
models to account for the competing risk of death.
23
 Second, we used a target trial 
emulation technique allowing for the inclusion of the individuals who died or developed 
ESKD during the six months after the eGFR decline to below 30 ml/min/1.73m
2 
with 
time-updated weighting (eMethods in the supplement).
24,25
 Third, we excluded 
individuals with systolic blood pressure lower than 90 mmHg or serum potassium higher 





restricted the study population to individuals who had been on ACE-I/ARB for at least 
six months at the time of the eGFR decline. Fifth, we excluded individuals with AKI at 
the time of eGFR decline, defined as an increase in serum creatinine by >100% compared 
with the previous outpatient measure within 1 year. Sixth, we excluded patients with a 
history of cancer determined by ICD diagnosis codes. Seventh, we evaluated whether 
discontinuation after eGFR decline to 20 ml/min/1.73m
2
 had similar associations with the 
endpoints of interest. Finally, we used Rosenbaum’s approach to explore the sensitivity 
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of our findings to unmeasured confounding.
26,27
 All 95% confidence intervals (CIs) in the 
primary and sensitivity analyses were reported based on robust standard errors.  
Results 
Study population  
There were 3909 individuals from the Geisinger Health System who met the inclusion 
criteria, with a mean age of 73.7 years (standard deviation 12.6 years); 62% were women. 
There were 1235 individuals who discontinued ACE-I/ARB within the 6 months after 
eGFR fell below 30 ml/min/1.73m
2
 and 2674 individuals without such discontinuation. 
Compared to their counterparts, individuals who discontinued ACE-I/ARB were more 
often male, had slightly lower eGFR, higher serum potassium level, higher prevalence of 
congestive heart failure, and more likely to be on antiplatelet agents at the time of the 
eGFR decline (Table 4-1). On the other hand, they were less likely to have diabetes and 
less likely to be on statin and beta-blockers. Nearly all (N=1205, 98%) individuals in the 
discontinuation group were successfully matched to controls, resulting in a total of 2410 
individuals in the propensity-score matched sample. The two treatment groups were 
closely balanced on all baseline covariates after propensity-score matching, with the 
absolute standardized mean difference below 0.1 for all covariates.  
ACE-I/ARB discontinuation and mortality, MACE, and ESKD  
Over a median follow-up of 2.9 years, 434 (35.1%) of the 1235 individuals who 
discontinued ACE-I/ARB within six months after eGFR declined to below 30 
ml/min/1.73m
2
 and 786 (29.4%) of the 2674 individuals without discontinuation died 
within five years after T0 (Figure 4-1 a, b). Of note, 347 (28%) of the 1235 patients who 
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discontinued ACE-I/ARB within six months of the eGFR decline restarted therapy during 
the follow-up period. The association between ACE-I/ARB discontinuation and higher 
risk of mortality remained after adjusting for baseline covariates in the propensity-score 
matched sample (hazard ratio (HR): 1.39 [95% CI: 1.20-1.60]; Table 4-2).  
Over a median follow-up of 2.7 years, there was a higher risk of MACE during 
the five-year period among those with ACE-I/ARB discontinuation (n=494, 40.0%) 
compared with those who did not discontinue (n=910, 34.0%; Figure 4-2 a, b). The 
association between ACE-I/ARB discontinuation and MACE remained in the propensity-
score matched sample (HR: 1.37 [95% CI: 1.20-1.56]).  
 Over a median follow-up of 2.7 years, a slightly higher proportion of individuals 
developed ESKD within five years among those who discontinued ACE-I/ARB within 
six months after eGFR dropped below 30 ml/min/1.73m
2
 (N=87, 7.0%) compared with 
those who did not discontinue (N=176, 6.6%; Figure 4-3 a, b). In adjusted analysis 
within the propensity-score matched sample, ACE-I/ARB discontinuation was not 
significantly associated with risk of ESKD (HR: 1.19 [95% CI: 0.86-1.65]).  
 There was no effect modification of the associations of ACE-I/ARB 
discontinuation with mortality and MACE by baseline history of stroke, diabetes, 
congestive heart failure, or coronary artery disease. However, the presence of baseline 
diabetes modified the association between ACE-I/ARB discontinuation and ESKD 
(p=0.013). Of the 915 and 1982 individuals from the discontinuation and non-
discontinuation group, respectively, who had a baseline measure of urine albumin to 
creatinine ratio, urine protein to creatinine ratio, or dipstick, 1794 were included in the 
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propensity-score matched sample. There was no significant effect modification of the 
association of ACE-I/ARB discontinuation with mortality, MACE, and ESKD by the 
presence of macroalbuminuria.  
Additional outcomes 
Over a median follow-up of 2.3 years, individuals who discontinued ACE-I/ARB within 
six months after eGFR fell below 30 ml/min/1.73m
2
 had a lower risk of hyperkalemia 
(N=193, 15.6%) compared with those who did not discontinue (N=593, 22.2%; Figure 4-
S 2). In the propensity-score matched sample, the association remained significant (HR: 
0.65 [95% CI: 0.54-0.79]).  
Although the risk of AKI was slightly lower among individuals with ACE-I/ARB 
discontinuation (N=343, 27.8%) than those without (N=806, 30.1%) in the overall sample, 
the difference was not significant after accounting for baseline covariates in the 
propensity-score matched sample (HR: 0.92 [95% CI: 0.79-1.07]).  
ACE-I/ARB discontinuation after eGFR decline by  40%  
Among the 4251 individuals with an eGFR decline by  40% over one year while on 
ACE-I/ARB, 1189 discontinued ACE-I/ARB within six months of the eGFR decline and 
the remaining 3062 did not (Table 4-S 3). Over a median follow-up of 3.3 years, a higher 
proportion of individuals who discontinued ACE-I/ARB died (N=388; 32.6%) compared 
with those without discontinuation (N=627; 20.5%). A similar trend held for 5-year 
MACE, with 448 (37.7%) and 777 (25.4%) individuals experiencing MACE among those 
with and without ACE-I/ARB discontinuation, respectively. The proportion of 
individuals developing ESKD was also slightly higher among those with ACE-I/ARB 
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discontinuation (48; 4.0%), compared with those without discontinuation (63; 2.1%) 
(Figure 4-1 - Figure 4-3 c, d). In adjusted analyses within the propensity-score matched 
sample, ACE-I/ARB discontinuation was associated with a higher risk of mortality (HR: 
1.53 [95% CI: 1.31-1.79]), MACE (HR: 1.40 [95% CI: 1.22-1.62]), but not ESKD (HR: 
1.50 [95% CI: 0.91-2.47]).   
Negative control 
Individuals who discontinued ACE-I/ARB within six months after eGFR fell below 30 
ml/min/1.73m
2
 showed similar risks of bleeding compared with their propensity-score 
matched peers without discontinuation (Figure 4-S 3; HR: 0.88 [95% CI: 0.66-1.16]). 
Sensitivity analysis 
All sensitivity analyses yielded similar associations of ACE-I/ARB discontinuation with 
mortality, MACE, and ESKD (Results in the supplement). Our results were moderately 
sensitive to an unobserved confounder. To attribute the observed associations to an 
unobserved covariate that increased the odds of mortality and MACE by 50%, the 
covariate would need to more than double the odds of ACE-I/ARB discontinuation.  
Discussion 
In this large, real-world study of individuals who experienced eGFR decline while on 
ACE-I or ARB therapy, discontinuation of therapy after eGFR decline was associated 
with a higher risk of death and MACE, but no statistically significant difference in the 
risk of ESKD. The findings were robust to a number of sensitivity analyses including 
using a target trial emulation technique, and excluding individuals with hypotension, 
hyperkalemia, AKI, or a history of cancer at the time of the eGFR decline. ACE-I/ARB 
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discontinuation was associated with a lower risk of hyperkalemia, consistent with 
existing evidence;
7
 however, this risk did not appear to outweigh the potential 
cardiovascular and survival benefits of continuing ACE-I/ARB therapy.  
Although our study is one of the first to evaluate the long-term risks of ACE-
I/ARB discontinuation among individuals who experience CKD progression, others have 
evaluated the association of ACE-I/ARB use with long-term outcomes or discontinuation 
with short-term changes in eGFR. A meta-analysis of clinical trials showed that ACE-
I/ARB use reduced risk of kidney failure and cardiovascular events in patents with 
CKD.
28
 Similarly, an observational cohort study of US veterans with CKD found survival 
benefits associated with the administration of ACE-I/ARB across all eGFR levels, 




 A trial randomizing 224 patients with serum 
creatinine levels of 3.1 to 5.0 mg/dL to benazepril or placebo showed a 43% lower risk of 
the composite of doubling of serum creatinine, ESKD, or death associated with 
benazepril.
13
 Post hoc, secondary analyses of the RENAAL trial and the REIN trial both 
suggested benefits of ACE-I/ARB in individuals with low GFR.
14,15
 However, an 
observational study of 52 individuals with stage G4 or 5 CKD reported an eGFR increase 
after ACE-I/ARB discontinuation, and the authors concluded “discontinuation of 
ACEi/ARB has undoubtedly delayed the onset of RRT [renal replacement therapy] in the 
majority of those studied”.
12
 An ongoing clinical trial aims to detect the difference in 3-
year GFR among individuals with stage G4-5 CKD.
16
 Our results add a longer 
observation period, a larger sample size of individuals with eGFR below 30 
ml/min/1.73m
2
, and ascertainment of hard outcomes with less concern for acute effects in 
GFR due to therapy. 
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Our study had several limitations. First, ACE-I/ARB use was obtained through 
prescription records and we could not verify actual medication dispensation or intake. 
Second, our study was observational and susceptible to unmeasured confounding. 
However, the two comparison groups were matched closely not only on measured 
clinical and demographic factors but also on variables including the number of outpatient 
visits, hospitalization status, and the presence of a nephrology visit during the year before 
eGFR decline. Third, we performed an intention-to-treat analysis providing an effect 
estimate based on the initial treatment decision; however, many patients who 
discontinued therapy then restarted ACE-I/ARB within the follow-up period. Thus, our 
effect estimate was likely conservative due to dilution caused by non-adherence to 
discontinuation status during follow-up.
30
 Fourth, we treated ACE-I/ARB discontinuation 
as binary without dose-response assessment. Fifth, ESKD is itself a treatment decision 
and likely varies by provider. Finally, the majority of our study population was white.  
Our study also had strengths. First, we used a “doubly robust” method to 
minimize confounding by indication through propensity-score matching and further 
adjustment for baseline demographic and clinical variables. Second, we conducted a 
number of sensitivity analyses with robust findings. Third, our study sample contained 
approximately 4000 individuals in routine clinical practice, which is a considerable 
sample size of ACE-I/ARB users with an eGFR decline to below 30 ml/min/1.73m
2
.  
Fourth, we assessed a negative control and observed similar risks of bleeding between the 
two treatment groups. This result helped mitigate concerns that the observed higher risks 
of death and MACE associated with ACE-I/ARB discontinuation might reflect poorer 
health status among those who discontinued ACE-I/ARB. Finally, we also studied 
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individuals who experienced  40% decline in eGFR within one year to address potential 
misclassification of advanced CKD and to provide additional insights for clinical practice.  
Conclusion  
We found a higher risk of mortality and MACE associated with ACE-I/ARB 
discontinuation after eGFR decline to below 30 ml/min/1.73m
2
, but no significant 
difference in the risk of ESKD. Similar patterns held for individuals with a  40% decline 
in eGFR. Our findings suggest that continuing ACE-I/ARB in patients with declining 
renal function may provide cardiovascular and survival benefits without excess risks of 
ESKD.  
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Figure 4- 1. Cumulative incidence of all-cause mortality, by ACE-I/ARB discontinuation status 
 
Note: 
a) Among patients with an eGFR decline to below 30 ml/min/1.73m
2
, full sample 
b) Among patients with an eGFR decline to below 30 ml/min/1.73m
2
, propensity-score matched sample 
c) Among patients with a   40% decline in eGFR within one year, full sample 
d) Among patients with a   40% decline in eGFR within one year, propensity-score matched sample 
Abbreviations: ACE-I, angiotensin-converting enzyme inhibitors; ARB, angiotensin II receptor blockers; eGFR, estimated 












Figure 4- 2. Cumulative incidence of MACE, by ACE-I/ARB discontinuation status 
 
Note: 
a) Among patients with an eGFR decline to below 30 ml/min/1.73m
2
, full sample 
b) Among patients with an eGFR decline to below 30 ml/min/1.73m
2
, propensity-score matched sample 
c) Among patients with a   40% decline in eGFR within one year, full sample 
d) Among patients with a   40% decline in eGFR within one year, propensity-score matched sample 
Abbreviations: ACE-I, angiotensin-converting enzyme inhibitors; ARB, angiotensin II receptor blockers; MACE, major adverse 











Figure 4- 3. Cumulative incidence of ESKD accounting for the competing risk of death, by ACE-I/ARB discontinuation status  
 
Note: 
a) Among patients with an eGFR decline to below 30 ml/min/1.73m
2
, full sample 
b) Among patients with an eGFR decline to below 30 ml/min/1.73m
2
, propensity-score matched sample 
c) Among patients with a   40% decline in eGFR within one year, full sample 
d) Among patients with a   40% decline in eGFR within one year, propensity-score matched sample 
Abbreviations: ACE-I, angiotensin-converting enzyme inhibitors; ARB, angiotensin II receptor blockers; ESKD, end-stage kidney 











Table 4- 1. Baseline characteristics by ACE-I/ARB discontinuation status, before and after propensity-score matching 
Baseline Characteristics 















Age, mean (SD), years 73.0 (12.9) 74.0 (12.4) 0.083 73.1 (12.8) 73.3 (13.2) 0.011 
eGFR
a




23.2 (5.7) 25.5 (4.2) 0.462 23.6 (5.3) 23.9 (5.3) 0.073 
Potassium
a





125.0 (22.5) 127.1 (20.2) 0.095 125.3 (22.3) 125.4 (20.1) 0.004 




6.7 (5.5) 5.9 (4.5) 0.158 6.6 (5.4) 6.4 (5.0) 0.032 
Female, N (%) 711 (57.6) 1695 (63.4) 0.119 696 (57.8) 706 (58.6) 0.017 
Black race, N (%) 22 (1.8) 52 (1.9) 0.012 22 (1.8) 25 (2.1) 0.018 
Coronary artery disease
c
, N (%) 547 (44.3) 1180 (44.1) 0.003 533 (44.2) 528 (43.8) 0.008 
Congestive heart failure
c
, N (%) 404 (32.7) 807 (30.2) 0.055 395 (32.8) 398 (33.0) 0.005 
Diabetes
c
, N (%) 582 (47.1) 1332 (49.8) 0.054 572 (47.5) 589 (48.9) 0.028 
History of stroke
c
, N (%) 239 (19.4) 560 (20.9) 0.040 236 (19.6) 245 (20.3) 0.019 
Statin use, N (%) 694 (56.2) 1721 (64.4) 0.167 681 (56.5) 692 (57.4) 0.018 
Beta-blocker use, N (%) 709 (57.4) 1682 (62.9) 0.112 689 (57.2) 676 (56.1) 0.022 
Antiplatelet agent use, N (%) 524 (42.4) 1113 (41.6) 0.016 505 (41.9) 501 (41.6) 0.007 
Hospitalization
b
, N (%) 20 (1.6) 44 (1.7) 0.002 20 (1.7) 19 (1.6) 0.007 
Nephrology visit
b
, N (%) 206 (16.7) 512 (19.2) 0.064 204 (16.9) 188 (15.6) 0.036 
Calendar year, N (%) 
      
2004-2008 175 (14.2) 463 (17.3) 0.086 173 (14.4) 176 (14.6) 0.007 
2009-2013 449 (36.4) 1022 (38.2) 0.039 437 (36.3) 429 (35.6) 0.014 
2014-2019 611 (49.5) 1189 (44.5) 0.100 595 (49.4) 600 (49.8) 0.008 
a




 Assessed during the one-year window 
before baseline; 
c
 Any time before baseline. Abbreviations: ACE-I, angiotensin-converting enzyme inhibitors; ARB, angiotensin II 
receptor blockers; eGFR, estimated glomerular filtration rate
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Table 4- 2. Association of ACE-I/ARB discontinuation with overall mortality, MACE, and ESKD  
Hazard ratio (95% confidence interval)
a
 Overall mortality MACE ESKD 
ACE-I/ARB discontinuation after an eGFR 
decline to <30 ml/min/1.73m
2
 
1.39 (1.20-1.60) 1.37 (1.20-1.56) 1.19 (0.86-1.65) 
ACE-I/ARB discontinuation after an eGFR 
decline by ≥ 40% 
1.53 (1.31-1.79) 1.40 (1.22-1.62) 1.50 (0.91-2.47) 
a
 Adjusted for baseline age, gender, race, serum potassium level, systolic blood pressure, eGFR, history of stroke, congestive heart 
failure, diabetes, coronary artery disease, concurrent use of statin, antiplatelet agents, and beta-blockers, calendar year at the time of 
the eGFR decline, whether a patient was hospitalized, had a nephrology visit, and the number of outpatient encounters during the one-
year period prior to the eGFR decline in the propensity-score matched sample. 
Abbreviations: ACE-I, angiotensin-converting enzyme inhibitors; ARB, angiotensin II receptor blockers; eGFR, estimated 
glomerular filtration rate; MACE, major adverse cardiovascular events; ESKD, end-stage kidney disease.  
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Supplement 
Supplemental Methods. Target trial emulation 
As a sensitivity analysis, we used a target trial emulation technique allowing for the 
inclusion of the patients who died or developed ESKD during the six months after the 
eGFR decline to below 30 ml/min/1.73m
2
. In this method, T0 was considered the day 
after eGFR declined below 30 ml/min/1.73m
2
. All eligible patients were duplicated and 
assigned to either the strategy of ACE-I/ARB continuation or discontinuation within 6 
months. At each 30-day increment after T0, patients were assessed for compliance with 
the assigned treatment strategy. Those who deviated from the assigned treatment strategy 
were censored. For example, if a patient assigned to the continuation arm was not on 
ACE-I/ARB therapy at day 60, he would be censored at that time. To account for the 
selection bias potentially introduced by censoring, we applied time-varying weighting by 
the inverse probability of remaining on the assigned treatment strategy (i.e., remaining 
uncensored). Weights were determined using a pooled logistic regression model 
restricted to the first six months of follow-up with discontinuation as the outcome. The 
model included all baseline covariates, month and its quadratic term, and time varying 
covariates including eGFR, serum potassium level, systolic blood pressure, history of 
stroke, diabetes, congestive heart failure, coronary artery disease, hospitalization status, 
the number of outpatient encounters, and whether a patient had a nephrology visit during 
the one year prior to the beginning of each monthly interval, and concurrent use of statin, 
antiplatelet agents, and beta-blockers. Weights were truncated at the 99.5
th
 percentile. 
Then, we estimated the association of ACE-I/ARB discontinuation with death, MACE, 
and ESKD using pooled logistic regression. Outcome models included an indicator 
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variable for the assigned treatment strategy, month of follow-up and its quadratic term, 
and all the baseline covariates. 95% CIs of the HRs were estimated using a nonparametric 
bootstrap with 500 samples. 
Supplemental Results. Sensitivity analyses 
Using the Fine-Gray method accounting for the competing risk of death, ACE-I/ARB 
discontinuation was not significantly associated with increased risk of ESKD (sHR: 1.11 
[95% CI: 0.81-1.53]). Using the target trial emulation method in which patients were not 
required to survive free of ESKD for six months after eGFR dropped below 30 
ml/min/1.73m
2
, we detected similar associations of ACE-I/ARB discontinuation with 
mortality (HR: 1.59 [95% CI: 1.43-1.79]), MACE (HR: 1.51 [95% CI: 1.36-1.69]), and 
ESKD (HR: 1.26 [95% CI: 0.99-1.65]), adjusted for baseline covariates. 
Excluding patients with hypotension or hyperkalemia at the time of the eGFR 
decline yielded a subsample of 1028 and 2447 patients in the discontinuation and non-
discontinuation group, respectively. In the propensity-score matched cohort of 2052 
patients, we found substantively similar associations of ACE-I/ARB discontinuation with 
mortality (HR: 1.38 [95% CI: 1.18-1.61]), MACE (HR: 1.32 [95% CI: 1.14-1.52]), and 
ESKD (HR: 1.36 [95% CI: 0.94-1.98]). 
In another sensitivity analysis limited only to patients who had been on ACE-
I/ARB for at least six months at the time of the eGFR decline to below 30 ml/min/1.73m
2
, 
we identified 992 and 2281 patients from the discontinuation and non-discontinuation 
group, respectively. Based on the propensity-score matched sample of 1940 patients, we 
found similar patterns as ACE-I/ARB discontinuation appeared to be associated with 
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higher risks of mortality (HR: 1.30 [95% CI: 1.11-1.53]) and MACE (HR: 1.29 [95% CI: 
1.11-1.51]), but not significantly different risk of ESKD (HR: 1.22 [95% CI: 0.82-1.80]).    
Excluding people with apparent stage 2 acute kidney injury at the time of eGFR 
decline to below 30 ml/min/1.73m
2
, we yielded 925 and 2343 patients from the 
discontinuation and non-discontinuation group, respectively. Based on the propensity-
score matched sample of 1830 patients, we also found ACE-I/ARB discontinuation was 
associated with higher risks of mortality (HR: 1.34 [95% CI: 1.15-1.57]) and MACE (HR: 
1.33 [95% CI: 1.15-1.55]), but not ESKD (HR: 1.04 [95% CI: 0.73-1.49]).  
Excluding people with a history of cancer at the time of eGFR decline to below 
30 ml/min/1.73m
2
 yielded a sample of 930 and 2082 and individuals from the 
discontinuation and non-discontinuation group, respectively. Based on the propensity-
score matched sample of 1802 patients, ACE-I/ARB discontinuation was associated with 
higher risks of mortality (HR: 1.49 [95% CI: 1.24-1.78]) and MACE (HR: 1.43 [95% CI: 
1.21-1.69]) but not ESKD (HR: 1.40 [95% CI: 0.98-2.00]).  
Among the 1217 individuals with an eGFR decline to below 20 ml/min/1.73m
2
 
while on ACE-I/ARB therapy, 572 discontinued ACE-I/ARB within six months of the 
eGFR decline and the remaining 645 did not. A total of 514 (90%) individuals in the 
discontinuation group were successfully matched to controls, resulting in a total of 1028 
individuals in the propensity-score matched sample. Similarly, ACE-I/ARB 
discontinuation was associated with a higher risk of mortality (HR: 1.34 [95% CI: 1.10-
1.64]), MACE (HR: 1.27 [95% CI: 1.05-1.53]), but not ESKD (HR: 1.27 [95% CI: 0.89-




Table 4-S 1. Diagnosis and procedure codes used to define end-stage kidney disease 
(ESKD) 





Procedure Coding System 
(HCPCS) 







39.95, 54.98, 55.69, V56x, 585.5, 585.6, V42.0, 996.81 
International classification 
of disease, 10th edition, 
clinical modification (ICD-
10-CM) 
5A1Dx, 3E1M39Z, 0TYx, Z49x, N18.5, N18.6, Z94.0, 
T86.1x 
 
Note: The symbol “x” at the end of a code represents any characters. ESKD date was the 
earlier date of kidney transplant and dialysis. Kidney transplant date and dialysis date 
were both obtained from THE United States Renal Data System (USRDS), which 
covered through 7/31/2018. For the period after 7/31/2018, kidney transplant was coded 
as the date of ICD procedure codes of kidney transplant, or the first date of ICD diagnosis 
codes of kidney transplant in inpatient or problem list when there were at least another 
two ICD diagnosis codes of kidney transplant in other encounters within one year if 
procedure codes were not present. Similarly, for dialysis after 7/31/2018, it was defined 
as the date of ICD diagnosis code of stage V chronic kidney disease or ESKD when there 
was a CPT, HCPSC and ICD codes of dialysis within 7 days later, or the date of the first 
CPT, HCPSC and ICD codes of dialysis when there were at least three dialysis codes that 
covered longer than a month with intervals between any two consecutive codes within 
three months. 
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Table 4-S 2. International classification of disease, 9th and 10th editions, clinical 
modification (ICD-9-CM, ICD-10-CM) used to define disease conditions 
Disease Conditions ICD-9-CM codes ICD-10-CM codes 
Diabetes 250.x E10.x, E11.x, E13.x 
Congestive heart failure 428.x I50.x 
Coronary artery disease 
410.x, 411.0, 
411.8x, 412, 414.x, 
36.1x  
I21.x, I22.x, I23.x, I24.x, I25.x 
Stroke 43x, V12.54 I6x 















530.7, 530.82, 578x, 






626.2, 626.6, 430, 




568.81, 719.1x,  
784.7, 784.8, 786.3x 
K25.0, K25.2, K25.4, K25.6, K26.0, 
K26.2, K26.4, K26.6, K27.0, K27.2, 
K27.4, K27.6, K28.0, K28.2, K28.4, 
K28.6, K29.01, K29.21, K29.41, 
K29.51, K29.61, K29.71, K29.81, 
K29.91, K31.811, I85.01, I85.11, 
K22.6, K22.8, K92.0, K92.1, K92.2, 
K64.4, K64.8, K57.11, K57.13, 
K57.31, K57.33, K66.1, K62.5, 
K55.21, R31.9, R31.0, R31.29, 
N93.8, N92.0, N92.1, I60.9, I61.9, 
I62.1, I62.00, I62.9, S06.6X0A, 
S06.6X1A, S06.6X2A, S06.6X3A, 
S06.6X4A, S06.6X5A, S06.6X6A, 
S06.6X7A, S06.6X8A, S06.6X9A, 
S06.5X0A, S06.5X1A, S06.5X2A, 
S06.5X3A, S06.5X4A, S06.5X5A, 
S06.5X6A, S06.5X7A, S06.5X8A, 
S06.5X9A, S06.4X0A, S06.4X1A, 
S06.4X2A, S06.4X3A, S06.4X4A, 
S06.4X5A, S06.4X6A, S06.4X7A, 
S06.4X8A, S06.4X9A, S06.360A, 
S06.361A, S06.362A, S06.363A, 
S06.364A, S06.3605A, S06.366A, 
S06.367A, S06.368A, S06.369A, 
I31.2, R58, K66.1, M25.00, 
M25.019, M25.029, M25.039, 
M25.049, M25.059, M25.069, 
M25.073, M25.076, M25.08, R04.0, 
R04.1, R04.2, R04.9, R04.89 
Acute kidney injury 584.x N17.x 
 
Note: The symbol “x” at the end of a code represents any characters. 
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Table 4-S 3. Baseline characteristics of patients with ≥40% eGFR decline 
Baseline Characteristics 















Age, mean (SD), years 68.9 (13.2) 66.4 (13.2) 0.185 68.8 (13.1) 68.0 (13.1) 0.059 
eGFR
a
, mean (SD), ml/min/1.73m
2
 29.4 (13.5) 37.7 (13.1) 0.626 29.8 (13.4) 30.5 (12.5) 0.059 
Potassium
a





122.3 (21.4) 124.9 (20.1) 0.123 122.5 (21.4) 122.8 (20.9) 0.014 




7.1 (5.7) 6.7 (4.9) 0.080 7.1 (5.7) 7.1 (5.2) 0.007 
Female, N (%) 641 (53.9) 1809 (59.1) 0.104 632 (54.5) 658 (56.7) 0.045 
Black race, N (%) 20 (1.7) 92 (3.0) 0.087 20 (1.7) 15 (1.3) 0.035 
Coronary artery disease
c
, N (%) 458 (38.5) 1091 (35.6) 0.060 445 (38.4) 440 (37.9) 0.009 
Congestive heart failure
c
, N (%) 331 (27.8) 667 (21.8) 0.141 319 (27.5) 333 (28.7) 0.027 
Diabetes
c
, N (%) 557 (46.9) 1501 (49.0) 0.044 545 (47.0) 537 (46.3) 0.014 
History of stroke
c
, N (%) 197 (16.6) 480 (15.7) 0.024 193 (16.6) 198 (17.1) 0.012 
Statin use, N (%) 656 (55.2) 1877 (61.3) 0.124 644 (55.5) 638 (55.0) 0.010 
Beta-blocker use, N (%) 642 (54.0) 1618 (52.8) 0.023 631 (54.4) 635 (54.7) 0.007 
Antiplatelet agent use, N (%) 463 (38.9) 1134 (37.0) 0.039 450 (38.8) 441 (38.0) 0.016 
Hospitalization
b
, N (%) 19 (1.6) 69 (2.3) 0.048 19 (1.6) 23 (2.0) 0.026 
Nephrology visit
b
, N (%) 126 (10.6) 221 (7.2) 0.119 120 (10.3) 121 (10.4) 0.003 
Calendar year, N (%) 
      
2004-2008 158 (13.3) 538 (17.6) 0.119 157 (13.5) 164 (14.1) 0.017 
2009-2013 443 (37.3) 1120 (36.6) 0.014 432 (37.2) 446 (38.5) 0.025 
2014-2019 588 (49.5) 1404 (45.9) 0.072 571 (49.2) 550 (47.4) 0.036 
a




 Assessed during the one-year window 
before baseline; 
c
 Any time before baseline. Abbreviations: ACE-I, angiotensin-converting enzyme inhibitors; ARB, angiotensin II 
receptor blockers; eGFR, estimated glomerular filtration rate
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Figure 4-S 1. Derivation of study population 
 
 
Abbreviations: ACE-I, angiotensin-converting enzyme inhibitors; ARB, angiotensin II 





















Abbreviations: ACE-I, angiotensin-converting enzyme inhibitors; ARB, angiotensin II receptor blockers.  
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Chapter 5. Conclusion  
Synthesis of evidence 
Using electronic heath records data from the Geisinger Health System, this dissertation advanced 
the understanding of use of ACE-I/ARB in real-world clinical practice, and the risks and benefits 
associated with its use in individuals with low kidney function.  
Our results showed underutilization of ACE-I/ARB among individuals without recorded 
contraindications or allergy to ACE-I/ARB as only 43.1% of those with ACR > 300 mg/g and 
only 40.9% of those with diabetes and ACR >30 mg/g initiated ACE-I/ARB within 6 months of 
the ACR measurement. We found that higher levels of albuminuria were associated with a 
greater chance of ACE-I/ARB initiation. Our results provide evidence that albuminuria test 
results change medical management, suggesting that adherence to albuminuria testing provides 
one opportunity to enhance utilization of ACE-I/ARB.  
We also found that discontinuation of ACE-I/ARB was common in real-world clinical 
practice, especially for individuals with advanced CKD. We estimated that the majority of ACE-
I/ARB users had a discontinuation in therapy by 5 years since initiation. There were strong 
associations of advanced CKD stages with therapy discontinuation, with patients with G4 disease 
(eGFR: 15-29 ml/min/1.73 m
2
) more than twice as likely to discontinue therapy compared to 
people with eGFR  90 mL/min/1.73m2. However, ACE-I/ARB discontinuation after eGFR 
decline to below 30 ml/min/1.73m
2 
was found to be associated with a higher risk of mortality and 
MACE, and no significant difference in the risk of ESKD. Our findings suggest that continuing 
ACE-I/ARB in patients with declining renal function may provide cardiovascular and survival 
benefits without excess risks of ESKD.  
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Remaining questions and future directions 
The study population was primarily white. However, previous studies have shown increased risk 
of angioedema associated with ACE-I/ARB among black individuals.
1
 Thus, black individuals 
may be more likely to discontinue ACE-I/ARB therapy. Additionally, ACE-I/ARB is less 
effective in the black population.
2
 Therefore, the risk-benefit balance of ACE-I/ARB among 
individuals with advanced CKD stage may vary by race. Future studies are needed to assess 
whether similar patterns hold in other racial and ethnicity groups.  
Additionally, due to the observational nature of our study design, findings may be subject 
to unmeasured confounding. There is an ongoing clinical trial assessing the effect of stopping 
ACE-I/ARB among individuals with advanced CKD stages,
3
 however, the study evaluates 3-year 
eGFR difference as the primary outcome without providing evidence on hard outcomes such as 
mortality. Additional trials are needed with longer follow up period to investigate the effect of 
ACE-I/ARB discontinuation on cardiovascular and survival outcomes.  
Finally, the scope of this dissertation was evaluating the pattern and risk-benefit of ACE-
I/ARB use without taking dosage into consideration. KDIGO also recommends “reduce dose by 
50% in people with GFR <30 ml/min/1.73 m
2
” with regards to ACE-I/ARB use in individuals 
with CKD.
4
 To provide further evidence to maximize therapeutic potential of these medications, 
a next step would be to evaluate dosage of ACE-I/ARB in real-world clinical practice among 
individuals with advanced CKD.  
Clinical and public health impact 
Findings from this project have significant clinical and public health implications. We shed light 
on the real-world utilization pattern of ACE-I/ARB and the risk-benefit of discontinuing these 
medications in the setting of CKD. The findings have potentials of informing clinical guidelines 
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and real-world practice of prescribing ACE-Is and ARBs, which will affect numerous patients 
given how widely these agents are used.  
 By using real-world electronic health records data that cover a long period of time, this 
dissertation evaluated long-term impact of discontinuing ACE-I/ARB among individuals with 
advanced CKD. Additionally, our data captured a large number of real-world ACE-I/ARB users 
with advanced CKD, who tend to be under-represented in clinical trials. This study was one of 
the first to provide evidence for this patient group assisting their treatment decisions with regards 
to ACE-I/ARB discontinuation following CKD progression.  
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o First-authored three manuscripts published in peer-reviewed journals and presented findings at conferences.  
 First-authored a study assessing how the cost of conducting clinical trials differs across various global regions. 
 Teaching assistant for graduate courses: Principles of Epidemiology (2018-2019 and 2019-2020 academic years); Introduction to 
Clinical Trials (2019-2020 academic year); Causal Inference in Medicine and Public Health I (2019-2020 and 2020-2021 
academic years). 
 
Senior Analyst, Cancer Care Ontario, Toronto, ON                                  Oct. 2015–Aug. 2017 
Cancer Care Ontario is an agency of the provincial Government of Ontario responsible for improving cancer services. 
Provided real-world evidence (RWE) support using multiple clinical and claims databases for the Ontario New Drug Funding Program 
and the Provincial Drug Reimbursement Programs 
 Developed study protocols and conducted comparative effectiveness and health outcomes research to evaluate the safety and 
effectiveness of pharmaceutical products reimbursed in Ontario; set up study cohorts and performed statistical analysis; authored 
multiple internal reports, peer-reviewed manuscripts, and conference abstracts. 
 Developed cancer care quality indicators; assessed the utilization and government expenditures on oral chemotherapy drugs 
covered by the Ontario Drug Benefit Program. 
 
Research Officer (Apr.–Sept. 2015), Research Practicum (Jan.–Mar. 2015), University of Toronto, Toronto, ON 
 Conducted cost-effectiveness, comparative effectiveness, and health outcomes research based on multiple population-based 
datasets to evaluate treatment strategies for hepatocellular carcinoma, and health care utilization and costs attributable to the 
disease in Ontario; co-authored four research manuscripts. 
 First-authored a systematic literature review and meta-analysis to assess the benefit, safety, and cost-effectiveness of screening in 
patients diagnosed with Barrett’s esophagus. 
 Managed project timelines and supervised research students; assisted in drafting ethics review protocols.  
 
Epidemiology Practicum Student, St. Michael’s Hospital, Toronto, ON                 Apr. 2014–Aug. 2014 
 Assessed disparities in perinatal health outcomes between immigrant and native-born populations in Sweden using the Swedish 
Medical Birth Register; co-authored two manuscripts.  
 
Research Assistant, University of Wisconsin-Madison, Madison, WI                  Sept. 2012–Aug. 2013 
 Interviewed patients at five primary care clinics and performed statistical analysis to identify factors associated with patients’ trust 
in electronic health records used in primary care; first-authored a manuscript.  
 
PROFESSIONAL ACTIVITIES AND AWARD 
 Conducted peer reviews for the following journals: Informatics for Health and Social Care, Journal of the American Society of 
Nephrology, BMC Nephrology, American Journal of Epidemiology 




 SAS, R, STATA, TreeAge 
 
PEER-REVIEWED MANUSCRIPT PUBLICATIONS 
1. Qiao Y, Shin J, Chen TK, Inker LA, Coresh J, Alexander GC, Jackson JW, Chang AR, Grams ME. Association between renin-
angiotensin system blockade discontinuation and all-cause mortality among people with low estimated glomerular filtration rate. 
JAMA Internal Medicine. 2020 May 1;180(5):718-726.   
2. Qiao Y, Shin J, Chen TK, Sang Y, Coresh J, Vassalotti JA, Chang AR, Grams ME. Association of albuminuria levels with the 
prescription of renin-angiotensin system blockade. Hypertension. 2020 Dec;76(6):1762-1768.  
3. Qiao Y, Shin J, Sang Y, Inker LA, Secora A, Luo S, Coresh J, Alexander GC, Jackson JW, Chang AR, Grams ME. 
Discontinuation of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in chronic kidney disease. Mayo 
Clinic Proceedings. 2019 Nov;94(11):2220-2229.  
4. Qiao Y, Alexander GC, Moore TJ. Globalization of clinical trials: variation in estimated regional costs of pivotal trials, 2015-
2016. Clinical Trials. 2019 Jun;16(3):329-333. 
5. Stevenson JKR, Qiao Y, Chan KKW, Beca J, Isaranuwatchai W, Guo H, Schwartz D, Arias J, Gavura S, Dai WF, Kouroukis CT, 
Cheung MC. Improved survival in overweight and obese patients with aggressive B-cell lymphoma treated with rituximab-
containing chemotherapy for curative intent. Leuk Lymphoma. 2018 Dec 5:1-9. 
6. Secora AM, Shin J, Qiao Y, Alexander GC, Chang AR, Inker LA, Coresh J, Grams ME. Hyperkalemia and Acute Kidney Injury 
with Spironolactone Use Among Patients with Heart Failure. Mayo Clin Proc. 2020 Nov;95(11):2408-2419. 
7. Dai WF, Beca J, Guo XH, Isaranuwatchai W, Schwartz D, Rohini N, Arias J, Qiao Y, Gavura S, Redmond R, Ismail Z, Barbera L, 
Chan KKW. Are Population-based Patient-Reported Outcomes Associated with Overall Survival in Patients with Advanced 
Pancreatic Cancer? Cancer Medicine. 2020 Jan;9(1):215-224. 
8. Chan KKW, Guo H, Cheng S, Beca JM, Redmond R, Isaranuwatchai W, Qiao L, Earle C, Berry SR, Biagi JJ, Welch S, Meyers 
BM, Mittmann N, Coburn N, Arias J, Schwartz D, Dai WF, Gavura S, McLeod R, Kennedy ED. Real-world outcomes of 
FOLFIRINOX vs gemcitabine and nab-paclitaxel in advanced pancreatic cancer: A population-based propensity score-weighted 
analysis. Cancer Medicine. 2020 Jan;9(1):160-169. 
9. Thein HH, Qiao Y, Zaheen A, Jembere N, Sapisochin G, Chan KKW, Yoshida EM, Earle CC. Cost-effectiveness analysis of 
treatment with non-curative or palliative intent for hepatocellular carcinoma in the real-world setting. PLOS ONE. 2017 Oct 
10;12(10):e0185198.  
10. Thein HH, Isaranuwatchai W, Qiao Y, Wong K, Sapisochin G, Chan KKW, Yoshida EM, Earle CC. Cost-effectiveness analysis 
of potentially curative and combination treatments for hepatocellular carcinoma with person-level data in a Canadian setting. 
Cancer Medicine. 2017 Sep;6(9):2017-2033. 
11. Qiao Y, Hyder A, Bae SJ, Zarin W, O'Neill TJ, Marcon NE, Stein L, Thein HH. Surveillance in patients with Barrett's esophagus 
for early detection of esophageal adenocarcinoma: a systematic review and meta-analysis. Clinical and Translational 
Gastroenterology. 2015;6:e131. 
12. Anyiwe K, Qiao Y, De P, Yoshida EM, Earle CC, Thein HH. Effect of socioeconomic status on hepatocellular carcinoma 
incidence and stage at diagnosis, a population-based cohort study. Liver International. 2016;36(6):902-910. 
13. Thein HH, Qiao Y, Young SK, Zarin W, Yoshida EM, de Oliveira C, Earle CC. Trends in health care utilization and costs 
attributable to hepatocellular carcinoma, 2002-2009: a population-based cohort study. Current Oncology. 2016;23(3):e196-220. 
14. Urquia ML, Qiao Y, Ray JG, Liu C, Hjern A. Birth outcomes of foreign-born, native-born, and mixed couples in Sweden. 
Paediatric and Perinatal Epidemiology. 2015;29(2):123-130.  
15. Juarez S, Urquia ML, Mussino E, Liu C, Qiao Y, Hjern A. Preterm disparities between foreign and Swedish born mothers depend 
on the method used to estimate gestational age. A Swedish population-based register study. PLOS ONE. [Accepted on February 2, 
2021] 
16. Qiao Y, Asan O, Montague E. Factors associated with patient trust in electronic health records used in primary care settings. 
Health Policy and Technology. 2015;4(4):357-363. 
 
SELECTED CONFERENCE PRESENTATIONS 
1. Poster presentation: “Globalization of clinical trials: variation in estimated regional costs of pivotal trials, 2015-2016”. ISPE’s 
35th International Conference on Pharmacoepidemiology and Therapeutic Risk Management. Philadelphia; August 2019.  
2. Moderated poster presentation: “Discontinuation of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in 
chronic kidney disease”. 2019 American Heart Association EPI Lifestyle Conference. Houston; March 2019. 
3. Poster presentation: “The effectiveness and cost-effectiveness of implementing bicycle lanes in the prevention of obesity and 
permanent severe injury.” 37th Annual Meeting of the Society for Medical Decision Making. St. Louis, Missouri; October 2015.  
4. Poster presentation: “Screening and surveillance in patients with Barrett’s esophagus for early detection of esophageal 
adenocarcinoma: a systematic review and meta-analysis.” Ontario Institute for Cancer Research/ Cancer Care Ontario Health 
Services Research Program 7th Annual Meeting. Toronto, Ontario; June 2015. 
5. Oral presentation: “Factors associated with patient trust in electronic health records used in a primary care setting: results from a 
survey.” Fourth International Conference on Health, Wellness & Society. Vancouver, British Columbia; March 2014. 
